

# JAIME D. MORIGUCHI , MD, FACC

## CURRICULUM VITAE

April 13<sup>th</sup>, 2021

### PROFESSIONAL CONTACT INFORMATION

Business Address: Cedars-Sinai Medical Center  
8700 Beverly Blvd  
Los Angeles, CA 90048

California Heart Center  
8670 Wilshire Blvd, 2<sup>nd</sup> Floor  
Beverly Hills, CA 90211

Phone: (310) 248-8300  
Fax: (310) 248-8333  
Email: [Jaime.Moriguchi@cshs.org](mailto:Jaime.Moriguchi@cshs.org)

### EDUCATION:

#### **Undergraduate**

Stanford University, Stanford, CA 1973-1977  
B.S., June 1977

#### **Premedical and Medical Education**

UCLA Medical Center, Los Angeles, California 1977-1981  
M.D. with Honors, June 1981

#### **Internship**

UCLA Medical Center, Los Angeles, CA 1981-1982  
Roy T. Young, M.D., Chief of Medicine  
Medical Internship

#### **Residency**

UCLA Medical Center, Los Angeles, California 1982-1984  
Roy T. Young, M.D., Chief of Medicine  
Medical Residency

UCLA Medical Center, Los Angeles, California 1984-1985  
Kenneth I. Shine, M.D., Chairman, Dept. of Medicine  
Chief Residency, Department of Medicine

#### **General Cardiology Fellowship**

UCLA Medical Center, Los Angeles, California 1985-1987  
Alan M. Fogelman, M.D., Chief of Cardiology  
Cardiology Fellowship

**LICENSURE:**

California Medical License, #G048967  
Drug Enforcement Administration (DEA), AM 1914781  
National Provider Identifier (NPI), 1265520001

**BOARD CERTIFICATION:**

American Board of Internal Medicine, Internal Medicine	1984 –
American Board of Internal Medicine, Cardiovascular Disease	1987 –
American Board of Internal Medicine, Medical Specialties, Advanced Heart Failure, Transplantation/MCS	2010

**PROFESSIONAL EXPERIENCE:**

**Present Position:**

2002- Clinical Professor of Medicine

**Previous Position:**

1985-1986	Chief Resident, Department of Medicine
1989-1995	Assistant Clinical Professor of Medicine
1995-2002	Associate Clinical Professor of Medicine

**PROFESSIONAL ACTIVITIES:**

**Committee Services:**

2010-	Heart Transplant Executive Committee
2010-	Heart Transplant Selection Committee
2010-	MCS PI Committee Chairman
2010-	MCS Core Committee
2010-	Mechanical Circulatory Support Executive Committee
2010-	Heart Failure Research Steering Committee
2019-	Syncardia Total Artificial Heart Committee

**Professional Associations/Society Memberships:**

1985-1986	House Staff Policy Committee
1985-1986	Internship Selection Committee
1986-1987	Peer Review Committee
1988-1990	Morbidity & Mortality Committee
1988-2009	Heart Transplant Executive Committee
1989-1990	Utilization Review
1991-2009	Infectious Disease Committee
1998-2009	Heart Transplant Selection Committee
2002-2004	Medical Staff Executive Committee

**RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:**

**Active/Ongoing:**

<b>Syncardia</b>	<b>Trento (site PI)</b>	<b>2015-</b>
<b>Syncardia 70 cc Temporary Total Artificial Heart for Destination Therapy Study. Role: Co-Investigator</b>		

**Syncardia** **Trento (site PI)** **2015-**  
**Syncardia 50 cc** Temporary Total Artificial Heart for Destination Therapy Study. Role: Co-Investigator

**Abbott** **Ramzy (site PI)** **2015-**  
**MOMENTUM 3** (Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with HeartMate 3™. Role: Co-Investigator

**Abbot** **Ramzy (site PI)** **2016-**  
**MOMENTUM 3 CAP** Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up. Role: Co-Investigator

**NIH/Duke University** **Kransdorf (Site PI)** **2017-**  
**Entresto™ (LCZ696) In Advanced Heart Failure (Life Study).** The purpose of this study is to evaluate the effects of LCZ696 (Entresto) compared to valsartan by evaluating NT-proBNP levels. The hypothesis is that patients with symptomatic heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve NT-proBNP levels. The study is a randomized, double-blinded trial of advanced heart failure subjects. Role: Co-Investigator

**Amgen** **Chang (Site PI)** **2018-**  
**GALACTIC:** A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction. Role: Co-Investigator

#### **Completed:**

**Janssen & Janssen LLC** **Moriguchi (site PI)** **2016-2020**  
**AC-055-205** - to evaluate the effect of the study drug, macitentan, on the properties and function of the heart and on the blood pressure in the pulmonary arteries and to find out more about the safety of the study drug in subjects with PH after LVAD implantation.

**Montreal Heart Institute** **Moriguchi (site PI)** **2019-2020**  
**TAH Registry** – a multicenter, retrospective registry is to review TAH patient data to better understand the profile of patients selected for TAH implant and timing of the implant as factors in post-implant outcomes and post-transplant outcomes

#### **RESEARCH FOCUS AND INTERESTS:**

Throughout this journey, my passion and energy has been devoted to the mechanical circulatory support (MCS) program serving as the Medical Director. The majority of our patients are critically ill with cardiogenic shock and we have developed a very strong VA ECMO and percutaneous MCS program as bridge to transplantation (BTT). We also implant durable LVADs for destination therapy and BTT. Over the past 7 yrs, we have also become one of the largest total artificial heart programs in the US (~100 implants).

## **INVITED LECTURES AND PRESENTATIONS:**

1. "Cardiac Transplantation: Medical Aspects" City of Hope Hospital Medical Grand Rounds, Duarte, CA, June 4, 1991
2. "Preoperative Evaluation of the Vascular Surgery Patient" Western Regional Vascular Surgery Symposium, October 1992
3. "Role of Antiplatelet Therapy in Preventive Medicine" UCLA Family Medicine Symposium, Huntington Ritz Carlton, Pasadena, CA, April 6, 1992
4. "Late Complications of Cardiac Transplantation" UCLA Cardiac Transplant Symposium, Marina Del Rey, CA, January 7, 1993
5. "Athletic Heart Syndrome" St. Joseph's Medical Center Cardiology Conference, October 12, 1993
6. "Modern Management of Congestive Heart Failure" UCLA Family Medicine Symposium, Miramar Sheraton, Santa Monica, CA, October 30, 1993
7. "Athletic Heart Syndrome" Centinela Medical Center Medical Grand Rounds, Inglewood, CA, April 11, 1994
8. "Therapeutic Strategies in ACE Inhibitor Therapy" Chapman General Hospital, June 6, 1994
9. "Cardiac Transplantation" Doctoring Curriculum, UCLA School of Medicine, January 9, 1995
10. "Athletic Heart Syndrome" Kaiser Permanente Cadillac, January 12, 1995
11. "Use of Nitrates in Angina and Acute Myocardial Infarction" Lakewood Regional Medical Center. Medical Grand Rounds, April 21, 1995
12. "Modern Management of Congestive Heart Failure" Suburban Medical Center. Medical Grand Rounds, April 27, 1995
13. "Late Complications of Cardiac Transplantation" UCLA International Symposium on Heart Failure & Heart Transplantation, Anaheim, CA, November 1995
14. "When to Refer Patients for Cardiac Transplantation" UCLA International Symposium on Heart Failure & Heart Transplantation, Anaheim, CA. November 1995
15. "Mechanical Assist Devices and the BVS 5000" Pomona Valley Medical Center (Dinner Symposium, October 20, 2001
16. "Recent Developments in Mechanical Cardiac Assistance and the Total Artificial Heart", Bakersfield Cardiology Symposium, October 27, 2001
17. "New Strategies in the Management of Acutely Decompensated CHF" Medical GRs MLK-Drew Hospital, October 30, 2001
18. Abiomed's Total Artificial Heart Symposium "AbioCor Recipient # 4 (UCLA)", November 8, 2001

19. "Mechanical Assist Devices & the TAH" Harbor-UCLA General Hospital Cardiology Grand Rounds, December 3, 2001
20. "Mechanical Assist Devices & the TAH" Torrance Memorial Hospital Cardiology Grand Rounds, December 10, 2001
21. "Mechanical Assist Devices and the Total Artificial Heart" UCLA Department of Medicine Grand Rounds, January 16, 2002
22. "Recent Advances in Ventricular Assist Devices and the Total Artificial Heart" UCLA Cardiology Grand Rounds, January 18, 2002
23. "Mechanical Assist Devices and the Total Artificial Heart" Medicine Grand Rounds West Hills Medical Center, February 22, 2002
24. BNP: Therapeutic Applications in the Post-op Surgical Patient – Cardiothoracic Surgery Educational Meeting, March 9, 2002
25. "Mechanical Circulatory Support and the Total Artificial Heart" Anesthesiology Grand Rounds, April 3, 2002
26. "Nesiritide: Therapeutic Applications in the Post-op Surgical Patient" Kaiser CTS and Cardiac Anesthesiology Grand Rounds, April 23, 2002
27. "Nesiritide: Therapeutic Applications in the Post-op Surgical Patient" Morton's/Orange County physicians, April 25, 2002
28. "Sudden Cardiac Death." Medical Grand Rounds; Community Memorial Medical Center Buenaventura, May 4, 2002
29. "Acute Management of Congestive Heart Failure Medical Grand Rounds; Brotman Medical Center, June 20, 2002
30. "Cardiac Resynchronization Therapy" Journal Club Medical Residents/Lawrence Library Presenter: Eun Kim, July 23, 2002
31. "Use of Nesiritide in the Post-op Surgical Patient" The Rittenhouse, Philadelphia, September 26, 2002
32. "Therapeutic Applications of Nesiritide in the Post-op Surgical Patient" Philadelphia Medical Center GRs, September 27, 2002
33. "Management of Acute CHF in the 21st Century – UCLA ED Grand Rounds, October 1, 2002
34. "Management of Acute Congestive Heart Failure – Role of Nesiritide" Haile Maile Plantation House, October 3, 2002
35. Management of Acute CHF" Maui Memorial Hospital Medical GRs, October 4, 2002
36. "New Approaches to the Management of Acute Congestive Heart Failure" Kaiser Medical Center GRs (Moanalua)", October 4, 2002

37. Mechanical Assist Devices and the Total Artificial Heart Bakersfield (Mercy Hospital) Symposium, November 13, 2002
38. Management of Hypertension and Risk Factor Reduction in the New Millennium Mastro's Steakhouse, January 30, 2003
39. "Current Status of Mechanical Assist Devices and the Total Artificial Heart" Cardiology GRs UCLA, February 7, 2003
40. "Current Status of Ventricular Assist Devices and the Total Artificial Heart" Pathology GRs UCLA, February 19, 2003
41. "Current Status of Ventricular Assist Devices and the Total Artificial Heart" Harbor-UCLA Grand Rounds, March 11, 2003
42. "The Hope Study" UCLA Endocrine GR's, April 4, 2003
43. "Current Status of Mechanical Assist Devices and the TAH" UCLA Heart Failure and Transplant Symposium Four Seasons Santa Barbara, May 3, 2003
44. "Left Ventricular Assist Devices and the Total Artificial Heart" Case Manager's Symposium Riviera CC, May 15, 2003
45. "New Technologies in Clinical Cardiology: Family Medicine Symposium BH Hotel, May 29, 2003
46. Kansas City Symposium on Heart Failure and Transplantation, Collaboration b/w Tertiary Centers and the Community, June 7, 2003
47. Kansas City Symposium on Heart Failure and Transplantation, Management of Acute Decompensated Heart Failure, June 7, 2003
48. "Cardio-renal Syndrome and Advanced Heart Failure "Kaiser Moanalua Medical Center Honolulu, Hawaii ", September 16, 2003
49. "CRT, LVADs and Beyond" Medtronic's Dinner Symposium Hawaii Prince Hotel, September 16, 2003
50. "What's New in Cardiothoracic Surgery: Management of Advanced Heart Failure" St Francis Medical Center Honolulu Hawaii, September 19, 2003
51. Current Management of Advanced Heart Failure: CRT, LVADs and Beyond "Sage and Onion Restaurant Santa Barbara, October 21, 2003
52. "Left Ventricular Assist Devices and the Total Artificial Heart: UCLA Symposium 'Cutting Edge Therapy in Heart Failure' Las Vegas Four Seasons Hotel, February 21, 2004
53. "Advances in Mechanical Circulatory Support" UCLA Division of Cardiology Grand Rounds, March 5, 2004
54. "Technological Advances in Clinical Cardiology" UCLA Family Medicine Symposium Beverly Hill Hotel,

June 3, 2004

55. "Sudden Cardiac Death" Torrance Memorial Hospital Medical Grand Rounds, June 9, 2004
56. "Recent Advances in the Management of Advanced Heart Failure" Tarzana-Encino Medical Center Medical Grand Rounds, June 22, 2004
57. Technological Advances in the Management of End-Stage Heart Failure Blue Cross-Blue Shield Case Managers Conference, June 23, 2004
58. Contemporary Management of Acute Decompensated and Advanced Heart Failure Community Memorial Hospital of Ventura County. Medical Grand rounds, August 30, 2004
59. 'Ventricular Assist Devices and the Total Artificial Heart' Cutting Edge Therapy for Advanced Heart Failure, Newport Beach UCLA CME, October 9, 2004
60. Current Status of Ventricular Assist Devices and the Total Artificial Heart Fujisawa Preceptorship, October 20, 2004
61. "Ventricular Assist Devices and other Surgical procedures for Advanced Heart Failure", Heart Failure University LAX Hilton, November 14, 2004
62. Cardiovascular complications in the Perioperative Patient General Surgery Interns conference, December 13, 2004
63. Advances in Device Therapy for Advanced Heart Failure, February 2, 2005  
Queens Medical Center Cardiology  
Medtronic's Symposium
64. Contemporary Management of Advanced Heart Failure Kaiser Moanalua Medical Center Cardiology Grand Rounds, February 2, 2005
65. Device Therapy for Management of Advance Heart Failure Pacific Cardiology Medical Group Symposium, Prince Hotel, February 3, 2005
66. Recent Advances in Device Therapy for Advanced Heart Failure: SCD-HeFT and Beyond. Straub Cardiology Symposium Honolulu, Hawaii, February 4, 2005
67. Mechanical Circulatory Support: Bridge to Transplant, Destination or Recovery.  
UCLA Division of Cardiology Grand Rounds, March 4, 2005
68. "Left Ventricular Assist Devices and the Total Artificial Heart" UCLA and Foundation for Cardiovascular and Transplant Research Symposium (CME) Hilton Los Angeles North/Glendale Meeting Center, April 16, 2005
69. "Device Therapy in the Management of Heart Failure" SCD-HeFT, MADIT and Beyond....., June 21, 2005
70. "Nesiritide: Role in the Management of Heart Failure" San Pedro Peninsula Hospital, July 12, 2005

71. HeartMate II Presentation (Thoratec) Torrance Memorial Cardiology Grand Rounds, May 22, 2006
72. "Technological Advances in Cardiology" Family Medicine Refresher Course, Beverly Hills Hilton, June 9, 2006
73. "Role of Mechanical Circulatory Support in Advanced Heart Failure" Long Beach Memorial Grand Rounds, September 20, 2006
74. "Recent Advances in Mechanical Circulatory Support in Advanced Heart Failure", October 7, 2006  
UCLA Heart Failure and Transplant Symposium  
Oxnard Marriott Courtyard Hotel
75. "Contemporary Management of Advanced Heart Failure: Assist Devices and Total Artificial Hearts", Heart Failure University (Cardiology Fellow Symposium) Los Angeles Airport Sheraton Hotel, December 4, 2006
76. "Current Status of Mechanical Circulatory Support in Advanced HF" Cardiology Grand Rounds- UCLA Healthcare, February 16, 2007
77. "Management of Advanced Congestive Heart Failure" PriMed Symposium (Anaheim Convention Center), May 11, 2007
78. "Mechanical Circulatory Support in Advanced Heart Failure" UCLA Medicine Grand Rounds, February 20, 2008
79. "Update on Mechanical Circulatory Support" UCLA Cardiology Grand Rounds, March 7, 2008
80. "Advances in Mechanical Circulatory Support in Advance Heart Failure" Optimal Management and New Advances in Heart Failure CME Symposium Westin Bonaventure Downtown Los Angeles, October 11, 2008
81. "Mechanical Circulatory Support for Advanced Heart Failure" Torrance Memorial Cardiology Grand Rounds, November 3, 2008
82. RRUCLA VAD Program Presentation JCAHO Site Visit for Destination Therapy Accreditation, February 5, 2009
83. "How to beat the odds and stay healthy", Torrance Masonic Temple, February 22, 2009
84. "Management of Ventricular Assist Devices from Physical Therapists Perspective" RRUCLA Department of Physical Therapy, May 14, 2009
85. "Contemporary Management of Advanced Heart Failure" RRUCLA Emergency Department Grand Rounds, June 2, 2009
86. "Sudden Cardiac Death" (CME) San Joaquin Community Hospital (Bakersfield, CA), July 1, 2009
87. "Mechanical Circulatory Support in Advanced Heart Failure" Pelican Hill Resort UCLA CME Heart Failure and Transplant Symposium, October 3, 2009



88. "Update on Mechanical Circulatory Support in Advanced Heart Failure" Cedars-Sinai Heart Institute Grand Rounds; CME, June 8, 2010
89. "Mechanical Circulatory Support in Advanced Heart Failure" San Joaquin Community Hospital; Bakersfield CA CME GRs, July 7, 2010
90. "Recent Advances in Mechanical Circulatory Support" Cardiology Grand Rounds Torrance Memorial Hospital CME, July 26, 2010
91. "Controversies and Advanced Treatment of Cardiovascular Disease" The Tenth in the Series. Cedars-Sinai Medical Center Symposium, October 8, 2010
92. "Mechanical Circulatory Support: Patient / Device Selection and Outcomes" An Expert Review of Advanced Heart Failure Management, Los Angeles, CA, October 16, 2010
93. "Mechanical Circulatory Support in Advanced Heart Failure" Optimal Care and New Therapies in Advanced Heart Disease, Hotel Bakersfield, CA, May 21, 2011
94. "Mechanical Circulatory Support in Advanced Heart Failure" Optimal Care and New Therapies in Advanced Heart Disease, Las Vegas, NV, October 22, 2011
95. "Mechanical Circulatory Support in Advanced Heart Failure" Optimal Care and New Therapies in Advanced Heart Disease. Hyatt Newport Beach, CA, September 17, 2011
96. "Use of HeartMate II LVAD in Advanced Heart Failure", Kaiser Permanente – San Diego, April 9, 2012
97. "Practical Considerations for the Use of Mechanical Circulatory Support", Success with Failure: Advanced Heart Disease Symposium, Universal City, California, June 7, 2012
98. "Use of HeartMate II LVAD in Advanced Heart Failure", Providence-Tarzana Medical Center, July 16, 2012
99. "Mechanical Circulatory Support in Advanced Heart Failure," Optimal Care and New Therapies for Advanced Heart Disease, Riverside, California, September 15, 2012
100. "Destination Therapy and the Total Artificial Heart: Ready for Prime Time?" Success with Failure: Advanced Heart Disease Symposium - 2nd annual meeting, Universal City, California, March 7, 2013
101. "Troubleshooting and Maintenance of Ventricular Assist Devices" Optimal Care and New Therapies for Advanced Heart Disease, Long Beach, California, May 11, 2013
102. "Indications for MCS: The Importance of Patient and Device Selection" Experts in MCS Therapy: Current State of the Art, Century City, California, November 2, 2013
103. "Indications for Mechanical Circulatory Support for Heart Failure: Patient & Device Selection" Surgical Alternatives in Advanced Heart Failure, Honolulu, Hawaii, October 11, 2014
104. "Mechanical Circulatory Support in Advanced Heart Failure" California Heart Center Noon Lecture, Los Angeles, California, September 17, 2014

105. "Optimizing Patients Prior to Device Implant" A Global User's Guide to Mechanical Circulatory Support, Los Angeles, California, October 9-10, 2015
106. "Mechanical Circulatory Support- Current State" Cardiology Grand Rounds, La Jolla, CA, March 1, 2016
107. "Role of MCS & ECMO in Cardiogenic Shock" Cardiology Update 2016: Conventional Wisdom and Beyond, Torrance, California, April 29, 2016
108. "Evaluation Criteria for MCS: Predicting Success" Success with Failure: Advanced Heart Disease Symposium – 4th annual meeting, Culver City, California, June 3, 2016
109. "Contemporary Management of Advanced Heart Failure" Medical Grand Rounds Valley Presbyterian (Northridge, CA) CME, November 15, 2016
110. "Contemporary Management of Advanced Heart Failure" California Chapter of ACC CV Nursing Symposium Paso Robles, CA CME, February 24, 2017
111. "Mechanical Circulatory Support in Advanced Heart Failure" Bakersfield Cardiology Central Cardiology Heart Hospital, Bakersfield, CA, March 23, 2017
112. "Current Management Strategies in Advanced Heart Failure" in Update in CV Management, Torrance Memorial Medical Center, Torrance, CA (CME), April 7, 2017
113. "Heart Transplantation, Total Artificial Hearts and Mechanical Circulatory Support: Options for Advanced Heart Failure," OptumHealth Education Transplant Conference, Scottsdale, Arizona, April 16, 2018
114. "ECMO," Cardiology Update: Conventional Wisdom and Beyond, Torrance Memorial Medical Center, Torrance, CA, April 20, 2018
115. "Mechanical Circulatory Support in Advanced Heart Disease," Kaiser Sunset Cardiology Grand Rounds, Los Angeles, CA, September 13, 2018
116. "Patient/Device Selection – Including Percutaneous Short Term and Durable Devices/TAH," Harbor UCLA Cardiology Grand Rounds, Torrance, CA, December 10, 2018
117. "Mechanical Circulatory Support in Advanced Heart Disease," Kaiser Sunset Cardiology Grand Rounds, Los Angeles, CA, September 13, 2018
118. "Patient/Device Selection – Including Percutaneous Short Term and Durable Devices/TAH," Harbor UCLA Cardiology Grand Rounds, Torrance, CA, December 10, 2018
119. "Managing the MCS Patient: A Cardiologist's Perspective," Success with Failure: The Art and Science of Heart Failure Management, Marina Del Rey, California Heart Center, February 1, 2019
120. "Team Approach to the Patient & Device Selection Process," Syncardia TAH Summit, Chicago, Illinois, March 9, 2019
121. "Contemporary Management of Cardiogenic Shock: A Role of MCS," Clinical Advancements in

Cardiovascular Care, Pomona Valley Hospital Medical Center, March 16, 2019

122. “Contemporary Management of Cardiogenic Shock: Role of Temporary Mechanical Circulatory Support,” Abiomed Symposium, Phoenix, Arizona, December 12, 2019
123. “New Options in Mechanical Circulatory Support Devices,” Success with Failure: An Advanced Heart Disease Symposium, Marina del Rey, CA, February 21, 2020
124. “Cardiogenic Shock and Cardiac Replacement” a case study based conversation- Syncardia Zoom Symposium; You Tube, July 17, 2020
125. “ECMO in Adult Heart Transplantation; when should you think about it” ELSO Symposium 2020 Virtual presentation, Sept 26, 2020
126. Abiomed symposium: accelerated percut MCS in Card Shock; case present ZOOM, October 27, 2020
127. “Contemporary Management of Cardiogenic Shock: Role of percutaneous MCS UCI Grand Rounds Virtual presentation, Feb 2, 2021

### **TEACHING ACTIVITIES:**

#### Non-Clinical Teaching

1. “Use of Short-Term Mechanical Circulatory Support in Cardiogenic Shock” Abiomed CHIP training symposium on protected PCI. CSMC, October 13, 2016
2. “Contemporary Management of Advanced Heart Disease” YPO-G Symposium, Harvey Morse Auditorium, CSMC, April 20, 2017
3. “Choosing Wisely – Patient & Device Selection,” Success with Failure: A Multi-Disciplinary Approach to Heart Failure, Los Angeles, California Heart Center Foundation, May 11, 2018

## **BIBLIOGRAPHY/PUBLICATIONS**

### **Research Papers – Peer Reviewed:**

1. Kobashigawa J, Stevenson L, **Moriguchi J**, Westlake C, Wilmarth J, Kawata N, Chuck C, Lewis W, Drinkwater D, Laks H. Randomized study of high dose oral cyclosporine therapy for mild acute cardiac rejection. *J Heart Transplant* 1989; 8:53-8.
2. Walden JA, Stevenson LW, Dracup K, Wilmarth J, Kobashigawa J, **Moriguchi J**. Heart Transplantation May Not Improve Quality of Life for Patients with Stable Heart Failure. *Heart Lung*, 18:497-506, 1989.
3. Hamilton MA, Stevenson LW, Child JS, **Moriguchi JD**, Woo M. Acute Reduction of Atrial Overload During Vasodilator and Diuretic Therapy in Advanced Congestive Heart Failure. *Am J Cardiol*, 65:1209-1212, 1990.
4. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, **Moriguchi J**, Walden J. Importance of Hemodynamic Response to Therapy in Predicting Survival with Ejection Fraction  $\leq$  20% Secondary to Ischemic or Non-Ischemic Dilated Cardiomyopathy. *Am J Cardiol*, 66:1348-1354, 1990.
5. Stevenson L, Sietsema K, Tillisch J, Lem V, Walden J, Kobashigawa J, **Moriguchi J**. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. *Circulation* 1990; 81:78-85.
6. Kobashigawa J, Murphy F, Stevenson L, **Moriguchi J**, Kawata N, Kamjoo P, Brownfield E, Wilmarth J, Leonard L, Chuck C, Drinkwater D, Laks H. Low Dose Lovastatin Safely Lowers Cholesterol After Cardiac Transplantation. *Circulation* 1990;82(suppl IV): IV-281-283.
7. Hamilton MA, Stevenson LW, Child JS, **Moriguchi JD**, Walden J, Woo M. Sustained Reduction in Valvular Regurgitation and Atrial Volumes with Tailored Vasodilator Therapy in Advanced Congestive Heart Failure Secondary to Dilated (Ischemic or Idiopathic) Cardiomyopathy. *Am J Cardiol*, 67:259-263, 1991.
8. Stevenson LW, Hamilton MA, Tillisch JH, **Moriguchi JD**, Kobashigawa JA, Drinkwater D, Laks H, Creaser J. Decreasing Survival Benefit from Cardiac Transplantation for Outpatients as the Waiting List Lengthens. *J Am Coll Cardiol*, 18:919-925, 1991.
9. Kobashigawa J, Stevenson L, Brownfield E, **Moriguchi J**, Kawata N, Fandrich R, Drinkwater D, Laks H. Initial success of steroid weaning late after heart transplantation. *J Heart Lung Transplant* 1992; 11:428-30.

10. Stevenson LW, Warner SL, Hamilton MA, **Moriguchi JD**, Chelimsky-Fallick C, Fonarow GC, Kobashigawa J, Drinkwater DC, Laks H. Modeling Distribution of Donor Heart to Maximize Early Candidate Survival *Circulation* 1992; 86(suppl II): II-224-II-230.
11. Kobashigawa JA, Stevenson LW, Brownfield ED, **Moriguchi JD**, Kawata N, Hamilton R, Minkley R, Drinkwater DC, Laks H. Does Short-Course Induction with OKT3 Improve Outcome After Cardiac Transplantation: A Randomized Trial. *J Heart Lung Transplant* 1993; 12:250-8.
12. Chelimsky-Fallick C, Stevenson LW, Stevenson WG, Kobashigawa JA, Middlekauff HR, Saxon LA, Brownfield ED, **Moriguchi J**, Hamilton M, Drinkwater D, Laks H. Amiodarone Therapy Does Not Compromise Subsequent Cardiac Transplantation. *J Am Coll Cardiol* 1992; 20:1156-61
13. Kobashigawa JA, Stevenson LW, **Moriguchi JD**, Kawata N, Brownfield E, Drinkwater D, Laks H. Is an intravenous glucocorticoid pulse better than oral taper for asymptomatic cardiac rejection? A Randomized Trial. *J Am Coll Cardiol* 1993; 21:1142-4.
14. Kobashigawa JA, Stevenson LW, Johnson BL, **Moriguchi JD**, Kawata N, Drinkwater DC, Laks H. Influenza vaccine does not cause rejection after cardiac transplantation. *Transpl Proceedings* 1993;25:2738-2739.
15. Laks H, Gates RN, Ardehali A, Capouya ER, **Moriguchi JD**, Kobashigawa JA, Stevenson LW. Orthotopic Heart Transplantation and Concurrent Coronary Bypass. *J Heart Lung Transplant* 1993; 12:810-5.
16. Lee T, Hamilton M, Stevenson L, **Moriguchi J**, Fonarow G, Child J, Laks H, Walden J. Impact of left ventricular cavity size on survival in advanced heart failure. *Am J Cardiol* 1993; 72:672-767.
17. Stevenson LW, Warner SL, Steimle AE, Fonarow GC, Hamilton MA, **Moriguchi JD**, Kobashigawa JA, Tillisch JH, Drinkwater DC, Laks H. The impending crisis awaiting cardiac transplantation. *Circulation* 1994; 89:450-7.
18. Steimle AE, Stevenson LW, Fonarow GF, Hamilton MA, **Moriguchi JD**. Prediction of improvement in recent onset cardiomyopathy after referral for transplantation. *J Am Coll Cardiol* 1994; 23:553-559.
19. Kobashigawa JA, Carr JG, **Moriguchi JD**, et al. Pravastatin lowers cholesterol and appears to decrease transplant coronary artery disease: a randomized trial. *Circulation* 1994; 90:1-94.
20. Kobashigawa JA, Stevenson LW, Brownfield ED, Gleeson MP, **Moriguchi JD**, Kawata N, Minkley R, Drinkwater DC, Laks H. Corticosteroid weaning late after cardiac transplantation: Relation to HLA-DR matching and long-term metabolic benefits. *J Heart Lung Transplant* 1995; 14:963-7.

21. Middlekauff HR, Nitzsche EU, Hamilton MA, Schelbert HR, Fonarow GC, **Moriguchi JD**, Hage A, Saleh S, Gibbs GG. Evidence for preserved cardiopulmonary baroreflex control of renal cortical blood flow in humans with advanced heart failure: a positron emission tomography study. *Circulation*. 1995; 92:395-401.
22. Stevenson LW, Steimle AE, Fonarow GC, Kermani M, Kermani D, Hamilton MA, **Moriguchi JD**, Walden J, Tillisch JH, Drinkwater DC, Laks H. Improvement in exercise capacity of candidates awaiting heart transplantation. *J Am Coll Cardiol* 1995; 25:163-170.
23. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, **Moriguchi JD**, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. *N Engl J Med* 1995; 33:621-627.
24. Kobashigawa JA, Sabad A, Cogert G, **Moriguchi J**, Hamilton M, Hage A, Kawata N, Drinkwater DC, Laks H. Pretransplant panel reactive antibodies: Are they truly a marker for poor outcome after cardiac transplantation. *Circulation* 1996;94(supplII): II-294-II-297.
25. Nguyen AH, Garfinkel A, Walter DO, Hamilton MA, Fonarow GC, **Moriguchi JD**, Hage A, Weiss JN, Middlekauff HR. Dynamics of muscle sympathetic nerve activity in advanced heart failure patients. *Am J Physiol* 1996; H1962-H1969.
26. Drinkwater DC, Laks H, Blitz A, Kobashigawa A, Sabad A, **Moriguchi J**, Hamilton M. Outcomes of patients undergoing transplantation with older donor hearts. *J Heart Lung Transplant* 1996;15(7):684-691.
27. Middlekauff HR, Nguyen AH, Negrao CE, Nietzsche EU, Hoh CK, Natterson BA, Hamilton MA, Fonarow GC, Hage A, **Moriguchi JD**. Impact of acute mental stress on sympathetic nerve activity and regional blood flow in advanced heart failure: implications for "triggering" adverse cardiac events. *Circulation* 1997; 96:1835-1842.
28. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, **Moriguchi JD**, Tillisch JH, Woo MA. Impact of a comprehensive heart failure program on hospital readmission and functional status of patients with advanced heart failure. *J Am Coll Cardiol* 1997;30(3):725-733.
29. Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, **Moriguchi JD**, Kartashov A, Tillisch JH. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. *Circulation* 1997; 96:4,1165-9.
30. **Moriguchi J**, Kirklin J, Stevenson L, Boehmer J, Mullen G, Smart F, Rodeheffer R, Costanzo M, Naftel D, Bourge R, and the Cardiac Transplant Research Data Base. Risk factors for sudden unexpected death in nonurgent (Status II) patients awaiting cardiac transplantation. *J Heart Transpl* April 1997.

31. Laks H, Scholl FG, Drinkwater DC, Blitz A, Hamilton M, **Moriguchi J**, Fonarow G, Kobashigawa J. The alternate recipient list for heart transplantation: does it work? *J Heart Lung Transplant* 1997;16 (7):735-42.
32. Feliciano Z, Boyle N, Wiener I, Fonarow GC, Knight L, Woo MA, Hamilton M, **Moriguchi JD**. The impact of implantable cardioverter defibrillator therapy on survival in patients with nonischemic heart failure and syncope. *Arch Mal Coeur* 91, June 1998; Suppl III:182.
33. Hamilton MA, Stevenson LW, Fonarow GC, Steimle AE, Goldhaber JI, Child JS, Chopra IJ, **Moriguchi JD**, Hage A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. *Am J Cardiol* 1998; 81:443-447.
34. Kobashigawa JA, Laks H, Marelli D, **Moriguchi JD**, Hamilton MA, Fonarow G, Hage A, Kawata N. The University of California at Los Angeles experience in heart transplantation. *Clin Transpl* 1998; 303-10.
35. Kobashigawa JA, Leaf DA, Lee N, Gleeson M, Liu H, Hamilton MA, **Moriguchi JD**, Kawata N, Einhorn K, Herlihy E, Laks H. A controlled trial of exercise rehabilitation after heart transplantation. *N Engl J Med* 1999; 340:272-7.
36. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, **Moriguchi J**, Hamilton MA, Kobashigawa J, Laks H. A Trial of Inhaled Nitric Oxide in Heart Transplant Recipients with Pulmonary Hypertension. *Transplantation* 2001; 72(4): 638-41.
37. Marelli D, Laks H, Fazio D, Moore S, **Moriguchi J**, Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. *J Heart Lung Transplant* 2000; 19:496-503.
38. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, **Moriguchi J**, Hamilton MA, Kobashigawa J, Laks H. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. *Transplantation* 2001; 4: 638-641.
39. Marelli D, Laks H, Bresson J, Houston E, Fazio D, Tsai FC, Hamilton M, **Moriguchi J**, Fonarow GC, Ardehali A, Camara R, Burch C, Alejos JC, George B, Kawata N, Kobashigawa J. Sixteen-year experience with 1,000 heart transplants at UCLA. *Clin Transpl.* 2000;297-310.
40. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, **Moriguchi J**, Hamilton MA, Kobashigawa J, Laks H. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. *Transplantation* 2001; 4: 638-641.

41. Fairhurst RM, Kubak BM, Pegues DA, **Moriguchi JD**, Ha KF, Haley JC, Kobashigawa JA. Mycobacterium haemophilum infections in heart transplant recipients: case report and review of the literature. *Am J Transplant.* 2002 May;2(5):476-9
42. Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Ardehali A, Esmailian F, Hamilton M, Fonarow GC, **Moriguchi J**, Plunkett M, Hage A, Tran J, Kobashigawa JA, Laks H. Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs. *Am J Transplant.* 2002 Jul;2(6):539-45.
43. Pinderski LJ, Fonarow GC, Hamilton M, Fishbein MC, Marelli D, **Moriguchi J**, Cohen B, Kobashigawa JA. Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. *J Heart Lung Transplant.* 2002 Jun;21(6):818-21.
44. Tsai FC, Marelli D, Laks H, **Moriguchi J**, Sohper M, Bresson J, Moghaddam S, Kubak B, Esmailian F, Ardehali A, Plunkett M, Litwin P, Kobashigawa J. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. *Am J Transplant.* 2002 Aug;2(7):646-51
45. Martin SM, Laks H, Drinkwater DC, Stevenson LW, Kawata N, Kobashigawa JA, **Moriguchi JD**, Hamilton MA. Cardiac Transplantation: The UCLA Experience 1984 to 1990. In: Terasaki P, ed. *Clinical Transplantation 1990*. Los Angeles, CA: The Regents of the University of California, 1991:103-114
46. Ardehali A, Laks H, Drinkwater DC, Ziv ET, Sorensen TJ, Hamilton MA, Stevenson LW, **Moriguchi JD**, Kobashigawa JA. Cardiac Transplantation at UCLA. In: Terasaki P, Cecka JM, eds. *Clinical Transplants 1993*. Los Angeles, CA: The Regents of the University of California, 1994:119-128.
47. Kobashigawa JA, Laks H, Marelli D, **Moriguchi JD**, Hamilton MA, Fonarow G, Hage A, Kawata N. The University of California at Los Angeles Experience in Heart Transplantation. In: Terasaki P, Cecka JM, eds. *Clinical Transplants 1998*. Los Angeles, CA: The Regents of the University of California, 1998.
48. Kobashigawa JA, Einhorn K, Ro TK, Cassem J, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Laks H. Mild rejection in steroid-free heart transplant recipients: Is it of concern? *J Heart Lung Transplant* 1998; 17:84.
49. Kobashigawa JA, Ro TK, Einhorn K, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Cassem JD, Laks H. Redo heart transplants have increased incidence of transplant coronary artery disease: impact on long-term survival. *J Am Coll Cardiol* 1999.
50. JA Kobashigawa, **J.D. Moriguchi**, H. Laks, T.K. Ro, M.A. Hamilton, A. Hage, L. Wener, N. Kawata. Five-year follow-up of a randomized trial of pravastatin in heart transplant patients. *J Heart Lung Transplant* 1999.
51. J Chait, JA Kobashigawa, J Chuang, **J Moriguchi**, N Kawata, H Laks. Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients. *J Heart Lung Transplant* 1999.



52. Kobashigawa JA, **Moriguchi JD**, Chuang JM, et al. A randomized trial of tacrolimus versus neoral cyclosporine in heart transplant recipients. *J Am Coll Cardiol* 2000;35:222A.
53. Kobashigawa JA, Lin P, **Moriguchi JD**, Ro TK, Cassem JD, Hamilton MA, Hage A, Kawata N. Do Heart Transplant Patients on Corticosteroid –Free Immunosuppression Have Less Rejection? *Circulation* 1999 ;100(18):I-525.
54. Kobashigawa JA, Ro TK, **Moriguchi JD**, Lee R, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients. *J Heart Lung Transplant* 1999.
55. Kobashigawa JA, Devereaux D, **Moriguchi JD**, et al. Effect of race in outcomes after heart transplantation. *J Am Coll Cardiol* 2000;35:167A.
56. Kobashigawa JA, **Moriguchi JD**, Takemoto S, Chuang JM, Wener L, Yeatman L, Ro T, Devereaux D, Kawata N, Laks H. First Year Results of a Randomized Trial of Tacrolimus vs. Neoral Cyclosporine in Heart Transplant Patients. *J Heart Lung Transplant* 2000.
57. H. Laks, D. Marelli, D. Fazio, A. Sadeghi, A. Ardehali, M. Hamilton, **J. Moriguchi**, G. Fonarow, A. Hage, F. Esmailian, N. Kawata, J. Kobashigawa. Intermediate Term Results of the Alternate Recipient List for Heart Transplantation. *J Heart Lung Transplant* 2000.
58. R. Camara, J.A. Kobashigawa, S. Lackey, J.M. Chuang, **J.D. Moriguchi**, N. Kawata, H. Laks. Concern Regarding the Use of Orlistat (Xenical) For the Treatment of Obesity in Cardiac Transplant Recipients. *J Heart Lung Transplant* 2000.
59. D. Marelli, H. Laks, D. Fazio, A. Sadeghi, A. Ardehali, **J. Moriguchi**, E. Houston, M. Talamo, F. Esmailian, A. Hage, M. Hamilton, G. Fonarow, N. Kawata, J. Kobashigawa. The Use of Marginal Donor Hearts. *J Heart Lung Transplant* 2000.
60. **J.D. Moriguchi**, J.A. Kobashigawa, S. Takemoto, L. Wener, J. Tobis, R. Lee, N. Kumar, J.M. Chuang, N. Kawata, H. Laks. Development of Circulating IgG Class I Antibodies is Associated With Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) After Heart Transplant. *J Heart Lung Transplant* 2000.
61. **J.D. Moriguchi**, P. Bueno, J.A. Kobashigawa, J.M. Chuang, S. Lackey, R. Camara, N. Kawata, H. Laks. A Pilot Study of L-Arginine for Renal Insufficiency in Heart Transplant Recipients. *J Heart Lung Transplant* 2000.
62. J.M. Chuang, J.A. Kobashigawa, M. Mui, S. Lackey, R. Camara, **J.D. Moriguchi**, N. Kawata, M. Marks, A. Velleca, M. Brown, H. Laks. What are the Infectious Risks of Pets Immediately After Heart Transplant? *J Heart Lung Transplant* 2000.

63. **J.D. Moriguchi**, D. Devereaux, J.A. Kobashigawa, S. Lackey, R. Camara, A. Velleca, M. Marks, M. Brown, J.M. Chuang, N. Kawata, H. Laks. Long Term Effects of Medical Insurance on Heart Transplant Recipients. *J Heart Lung Transplant* 2000.
64. D Marelli, H Laks, **J Moriguchi**, D Fazio, M Hamilton, G Fonarow, A Hage, S Salehmoghaddam, B Kubak, D Meehan, M Talamo, A Sadeghi, F Esmailian, A Ardehali, M Plunkett, J Kobashigawa. Single Institution Outcome Analysis of 344 Consecutive Patients Receiving Donor Hearts Preserved Using University of Wisconsin Solution. *AST Chicago*, Chicago Sheraton Hotel, May 15, 2000.
65. Daniel Marelli, Michele A. Hamilton, Hillel Laks, Gregg C Fonarow, Daniel Fazio, **Jaime D. Moriguchi**, Saleh Saleh, Bernard Kubak, Abbas Ardehali, Fardad Esmailian, Antoine Hage, Jon A. Kobashigawa. Heart Transplantation in the Elderly. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. *Circulation* 2000;102: II-490.
66. Daniel Marelli, Hillel Laks, Daniel Fazio, **Jaime D. Moriguchi**, Gregg C. Fonarow, Saleh Salehmoghaddam, Bernard Kubak, Juan C. Alejos, Alvaro Galindo, Jon A. Kobashigawa. Clinical and Laboratory Studies in Thoracic Organ Transplantation. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. *Circulation* 2000;102: II-763.
67. G. Giesler, M. Espejo, B. Kubak, **J. Moriguchi**, J. Patel, H. Laks, J. Kobashigawa. Increased Risk of CMV Infection in Heart Transplant Patient on Mycophenolate Mofetil. *J Heart Lung Transplant* 2001; 20: 178.
68. K Shivkumar, M Espejo, J Kobashigawa, M Watanabe, M Ikeda, J Chuang, J Patel, **J Moriguchi**, M Hamilton, N Kawata, H Laks. Sudden Death After Heart Transplantation: The Major Mode of Death. *J Heart Lung Transplant* 2001; 20: 180.
69. M. Espejo, J. Kobashigawa, **J. Moriguchi**, J. Patel, N. Kumar, M. Hamilton, A. Hage, N. Kawata, H. Laks. The Dilemma of Disability After Heart Transplantation. *J Heart Lung Transplant* 2001; 20: 244.
70. D. Marelli, F. Tsai, H. Laks, E. Houston, J. Bresson, L. Friend, D. Gjertson, A. Sykes, A. Ardehali, F. Esmailian, M. Hamilton, G. Fonarow, **J. Moriguchi**, M. Plinkett, A. Hage, M. Brown, M. Mark, J. Kobashigawa. Use of Heart Transplanted from Donors with Atraumatic Intracranial Bleeds. *J Heart Lung Transplant* 2001; 20: 256.
71. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, **Moriguchi J**, Hamilton MA, Kobashigawa J, Laks H. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. *Transplantation* 2001; 4: 638-641.
72. Fairhurst RM, Kubak BM, Pegues DA, **Moriguchi JD**, Ha KF, Haley JC, Kobashigawa JA. Mycobacterium haemophilum infections in heart transplant recipients: case report and review of the literature. *Am J Transplant.* 2002 May;2(5);476-9.

73. Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Ardehali A, Esmailian F, Hamilton M, Fonarow GC, **Moriguchi J**, Plunkett M, Hage A, Tran J, Kobashigawa JA, Laks H. Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs. *Am J Transplant*. 2002 Jul;2(6):539-45.
74. Pinderski LJ, Fonarow GC, Hamilton M, Fishbein MC, Marelli D, **Moriguchi J**, Cohen B, Kobashigawa JA. Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. *J Heart Lung Transplant*. 2002 Jun;21(6):818-21.
75. Tsai FC, Marelli D, Laks H, **Moriguchi J**, Sohper M, Bresson J, Moghaddam S, Kubak B, Esmailian F, Ardehali A, Plunkett M, Litwin P, Kobashigawa J. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. *Am J Transplant*. 2002 Aug;2(7):646-51.
76. Marelli D, Kermani R, Bresson J, Fishbein MC, Hamilton M, **Moriguchi J**, Fonarow GC, Cohen B, Kobashigawa JA, Laks H. Support with the BVS® 5000 Assist Device during Treatment of Acute Giant-Cell Myocarditis. *Tex Heart Inst J*. 2003;30(1):50-6.
77. Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, **Moriguchi JD**, Bresson J, Gjertson D, Kobashigawa JA. Use of two recipient lists for adults requiring heart transplantation. *J Thorac Cardiovasc Surg* 2003;125(1):49-59.
78. Marelli D, Laks H, Bresson S, Ardehali A, Bresson J, Esmailian F, Plunkett M, **Moriguchi J**, Kobashigawa J. Results after transplantation using donor hearts with preexisting coronary artery disease. *J Thorac Cardiovasc Surg*. 2003 Sep;126(3):821-5.
79. Chantranuwat C, Blakey JD, Kobashigawa JA, **Moriguchi JD**, Laks H, Espejo Vassilakis M, Fishbein MC. Sudden, unexpected death in cardiac transplant recipients: An autopsy study. *J Heart Lung Transplant* 2004; 23:683-9.
80. Kobashigawa JA, **Moriguchi JD**, Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marquez A, Vassilakis ME, Patel J, Yeatman L. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. *J Heart Lung Transplant* 2005;24(11):1736-40.
81. Kobashigawa JA, Patel J, Furukawa H, **Moriguchi JD**, Yeatman L, Takemoto S, Marquez A, Shaw J, Oeser BT, Subherwal S, Wu GW, Kawano J, Laks H. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. *J Heart Lung Transplant* 2006;25(4):434-9.
82. Dracup K, Evangelista LS, Hamilton MA, Erickson V, Hage A, **Moriguchi J**, Candary C, MacLellan R, Fonarow GC. Effects of a Home-Based Exercise Program on Clinical Outcomes in Advanced Heart Failure. *Am Heart J* 2007.

83. Middlekauff HR, Chiu J, Hamilton MA, Fonarow GC, Maclellan WR, Hage A, **Moriguchi J**, Patel J. Cyclooxygenase products sensitive muscle mechanoreceptors in humans with heart failure. *Am J Physiol Heart Circ Physiol* 2008;294(4):H1956-62.
84. Vaseghi M, Lellouche N, Ritter H, Fonarow GC, Patel JK, **Moriguchi J**, Fishbein MC, Kobashigawa JA, Shivkumar K. Mode and mechanisms of death after orthotopic heart transplantation. *Heart Rhythm* 2009;6(4):503-9.
85. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, **Moriguchi JD**, Reed EF, Ardehali AA. The long-term outcome of treated sensitized patients who undergo heart transplantation. *Clin Transplant*. 2011 Jan-Feb;25(1): E61-7. doi: 10.1111/j.1399-0012.2010.01334. x. Epub 2010 Oct 25. PubMed PMID: 20973825; PubMed Central PMCID: PMC3829691.
86. Kittleson MM, Shemin R, Patel JK, Ardehali A, Kawano M, Davis S, **Moriguchi JD**, Kobashigawa JA. Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience. *J Heart Lung Transplant*. 2011 Sep;30(9):1018-22. doi: 10.1016/j.healun.2011.03.018. Epub 2011 May 8. PubMed PMID: 21550824.
87. **Moriguchi J**, Davis S, Jocson R, Esmailian F, Ardehali A, Laks H, Kwon M, Kittleson M, Kobashigawa J, Patel J, Marelli D, Plunkett M, Beygui R, Shemin R. Successful use of a pneumatic biventricular assist device as a bridge to transplantation in cardiogenic shock. *J Heart Lung Transplant*. 2011 Oct;30(10):1143-7. doi: 10.1016/j.healun.2011.04.005. Epub 2011 Jun 2. PubMed PMID: 21640618.
88. Kittleson MM, Patel JK, **Moriguchi JD**, Kawano M, Davis S, Hage A, Hamilton MA, Esmailian F, Kobashigawa JA. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. *J Heart Lung Transplant*. 2011 Nov;30(11):1250-6. doi: 10.1016/j.healun.2011.05.006. Epub 2011 Jun 14. PubMed PMID: 21676629.
89. Loh JC, Creaser J, Rourke DA, Livingston N, Harrison TK, Vandenbogaart E, **Moriguchi J**, Hamilton MA, Tseng CH, Fonarow GC, Horwich TB. Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. *Circ Heart Fail*. 2013 May;6(3):411-9. doi: 10.1161/CIRCHEARTFAILURE.112.000178. Epub 2013 Mar 11. PubMed PMID: 23479563; PubMed Central PMCID: PMC3674961.
90. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, **Moriguchi J**, Esmailian F, Azarbal B. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. *Ann Thorac Surg*. 2014 Feb;97(2):610-6. doi: 10.1016/j.athoracsur.2013.09.008. Epub 2013 Nov 8. PubMed PMID: 24210621.
91. Caceres M, Czer LS, Esmailian F, Luthringer D, Ramzy D, **Moriguchi J**. Staged approach to mechanical circulatory support and recovered allograft function after transplantation rejection with cardiogenic shock. *Tex Heart Inst J*. 2013;40(5):596-9. PubMed PMID: 24391334; PubMed Central PMCID: PMC3853834.

92. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, **Moriguchi J**, Esmailian F, Azarbal B. Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. *J Card Fail.* 2014 Jun;20(6):400-6. doi: 10.1016/j.cardfail.2014.03.005. Epub 2014 Mar 15. PubMed PMID: 24642377.
93. Caceres M, Esmailian F, **Moriguchi JD**, Arabia FA, Czer LS. Mechanical circulatory support in cardiogenic shock following an acute myocardial infarction: a systematic review. *J Card Surg.* 2014 Sep;29(5):743-51. doi: 10.1111/jocs.12405. Epub 2014 Aug 1. PubMed PMID: 25080837.
94. Arabia FA, **Moriguchi JD**. Machines versus medication for biventricular heart failure: focus on the total artificial heart. *Future Cardiol.* 2014 Sep;10(5):593-609. doi: 10.2217/fca.14.47. Review. PubMed PMID: 25354032.
95. Awad M, Czer LS, Soliman C, Mirocha J, Ruzza A, Pinzas J, Rihbany K, Chang D, **Moriguchi J**, Ramzy D, Esmailian F, Kobashigawa J, Arabia F. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support. *ASAIO J.* 2015 Jul-Aug;61(4):391-6. doi: 0.1097/MAT.0000000000000231. PubMed PMID: 26125664; PubMed Central PMCID: PMC4487870.
96. Cheng R, Hachamovitch R, Makkar R, Ramzy D, **Moriguchi JD**, Arabia FA, Esmailian F, Azarbal B. Lack of Survival Benefit Found With Use of Intraaortic Balloon Pump in Extracorporeal Membrane Oxygenation: A Pooled Experience of 1517 Patients. *J Invasive Cardiol.* 2015 Oct;27(10):453-8. Epub 2015 Jul 15. PubMed PMID: 26208379.
97. Reich H, Ramzy D, Czer L, Esmailian F, **Moriguchi J**, Ihnken K, Yusufali T, D'Attellis N, Arabia F, Annamalai A. Hemodynamic Consequences of Laparoscopy for Patients on Mechanical Circulatory Support. *J Laparoendosc Adv Surg Tech A.* 2015 Dec;25(12):999-1004. doi: 10.1089/lap.2015.0295. Epub 2015 Nov 2. PubMed PMID: 26523797.
98. Reich HJ, Shah A, Azarbal B, Kobashigawa J, **Moriguchi J**, Czer L, Esmailian F. Microaxial Flow Left Ventricular Assist Device as a Bridge to Transplantation after LVAD Malfunction. *Tex Heart Inst J.* 2015 Dec 1;42(6):572-4. doi: 10.14503/THIJ-14-4654. eCollection 2015 Dec. PubMed PMID: 26664315; PubMed Central PMCID: PMC4665289.
99. Neyer J, Arsanjani R, **Moriguchi J**, Siegel R, Kobashigawa J. Echocardiographic parameters associated with right ventricular failure after left ventricular assist device: A review. *J Heart Lung Transplant.* 2016 Mar;35(3):283-93. doi:10.1016/j.healun.2015.12.018. Epub 2016 Jan 6. PubMed PMID: 26856675.
100. Arman D, Kuraitis D, **Moriguchi J**, Hamilton M, Liou F, Siddiqui S, Luu M, Zakowski P, Arabia F, Kobashigawa J. Do Prior Driveline Infections Increase the Risk of Infection in Heart Transplant Patients Treated with Rabbit Antithymocyte Globulin Induction Therapy? *Transplant Proc.* 2016 Dec; 48(10): 3393-6

101. Francisco A. Arabía, MD, MBA, Ryan S. Cantor, PhD, Devin A. Koehl, BS, Vigneshwar Kasirajan, MD, Igor Gregoric, MD, **Jaime D. Moriguchi**, MD, Fardad Esmailian, MD, Danny Ramzy, MD, PhD, Joshua S. Chung, MD, Lawrence S. Czer, MD, Jon A Kobashigawa, MD, Richard G. Smith, MSEE, CCE, James K. Kirklin, MD. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. *J Heart Lung Transplant*. 2017 Nov; 37(11): 1304-1312. DOI: <https://doi.org/10.1016/j.healun.2018.04.004>.
  
102. Cheng R, Ramzy D, Azarbal B, Arabia FA, Esmailian FA, Czer LC, Kobashigawa JA, **Moriguchi JD**. Device Strategies for Patients in INTERMACS Profiles 1 and 2 Cardiogenic Shock: Double Bridge With Extracorporeal Membrane Oxygenation and Initial Implant of More Durable Devices. *Artificial Organs*. 2017 March, 41(3); 224-232. doi: <https://doi.org/10.1111/aor.12758>.
  
103. Arabía FA, Milano CA, Mahr C, McGee EC Jr, Mokadam NA, Rame JE, **Moriguchi JD**, Ramzy D, Naftel DC, Myers SL, Kirklin JK. Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices. *Ann Thorac Surg*. 2018 Feb;105(2):548-555. doi: 10.1016/j.athoracsur.2017.08.019.
  
104. Kittleson MM, Cole RM, Patel J, Ramzy D, Passano E, Chang DH, Geft DR, Czer L, Vescio R, Chung J, Kobashigawa JA, Arabia F, Esmailian F, **Moriguchi JD**. Mechanical Circulatory Support for Cardiac Amyloidosis. *Clin Transplant*. 2019 July 15: e13663. Epub 2019/07/17. doi: 10.1111/ctr.13663. PubMed PMID: 31309629. In Press.
  
105. Setareh-Shenas S, Thomas F, Cole RM, Lemor A, Herzog E, Arabia FA, **Moriguchi J**; Evaluation of 30-Day Readmissions After Index Ventricular Assist Device Implantation in the United States; *American Society of Artificial Internal Organs Journal*; Aug 2019, doi 10.1097. PMID: 30299298
  
106. Cheng R, Tank R, Ramzy D, Azarbal B, Chung J, Esmailian F, Kobashigawa JA, **Moriguchi JD**, Arabia FA. Clinical Outcomes of Impella Microaxial Devices Used to Salvage Cardiogenic Shock as a Bridge to Durable Circulatory Support or Cardiac Transplantation. *ASAIO J*. 2019 Sep/Oct;65(7):642-648. doi: 10.1097/MAT.0000000000000877. PMID: 30281541.
  
107. Chung JS, Emerson D, Ramzy D, Akhmerov A, Megna D, Esmailian F, Kobashigawa J, Cole RM, **Moriguchi J**, Trento A. A New Paradigm in Mechanical Circulatory Support: 100-Patient Experience. *Ann Thorac Surg*. 2020 May;109(5):1370-1377. doi: 10.1016/j.athoracsur.2019.08.041. Epub 2019 Sep 26. PMID: 31563492.
  
108. Reich H, Ramzy D, **Moriguchi J**, Dimbil S, Levine R, Passano E, Kittleson M, Cole R, Czer L, Chang D, Geft D, Trento A, Chikwe J, Kobashigawa J, Esmailian F. Acceptable Post-Heart Transplant Outcomes Support Temporary MCS Prioritization in the New OPTN|UNOS Heart Allocation Policy. *Transplant Proc*. 2021 Jan- Feb;53(1):353-357. doi: 10.1016/j.transproceed.2020.04.1819. Epub 2020 Jul 7. PMID: 32650992.

109. Melmed KR, Schlick KH, Rinsky B, Dumitrascu OM, Volod O, Nezhad M, Padrick MM, Runyan C, Arabia FA, **Moriguchi JD**, Lyden PD, Song SS. Assessing Cerebrovascular Hemodynamics Using Transcranial Doppler in Patients with Mechanical Circulatory Support Devices. *J Neuroimaging*. 2020 May;30(3):297-302. doi: 10.1111/jon.12694. Epub 2020 Feb 10. PMID: 32037621.
110. Hitzeman TC, Xie Y, Zadikany RH, Nikolova AP, Baum R, Caldaruse AM, Agvanian S, Melmed GY, McGovern DPB, Geft DR, Chang DH, **Moriguchi JD**, Hage A, Azarbal B, Czer LS, Kittleson MM, Patel JK, Wu AHB, Kobashigawa JA, Hamilton M, Hong T, Shaw RM. cBIN1 Score (CS) Identifies Ambulatory HFref Patients and Predicts Cardiovascular Events. *Front Physiol*. 2020 May 25;11:503. doi: 10.3389/fphys.2020.00503. eCollection 2020. PMID: 32670075
111. Chung JS, Emerson D, Ramzy D, Akhmerov A, Megna D, Esmailian F, Kobashigawa J, Cole RM, **Moriguchi J**, Trento A. A New Paradigm in Mechanical Circulatory Support: 100-Patient Experience. *Ann Thorac Surg*. 2020 May;109(5):1370-1377. doi: 10.1016/j.athoracsur.2019.08.041. Epub 2019 Sep 26. PMID: 31563492.
112. Hitzeman TC, Xie Y, Zadikany RH, Nikolova AP, Baum R, Caldaruse AM, Agvanian S, Melmed GY, McGovern DPB, Geft DR, Chang DH, **Moriguchi JD**, Hage A, Azarbal B, Czer LS, Kittleson MM, Patel JK, Wu AHB, Kobashigawa JA, Hamilton M, Hong T, Shaw RM. cBIN1 Score (CS) Identifies Ambulatory HFref Patients and Predicts Cardiovascular Events. *Front Physiol*. 2020 May 25;11:503. doi: 10.3389/fphys.2020.00503. PMID: 32670075; PMCID: PMC7326053.
113. Melmed KR, Schlick KH, Rinsky B, Dumitrascu OM, Volod O, Nezhad M, Padrick MM, Runyan C, Arabia FA, **Moriguchi JD**, Lyden PD, Song SS. Assessing Cerebrovascular Hemodynamics Using Transcranial Doppler in Patients with Mechanical Circulatory Support Devices. *J Neuroimaging*. 2020 May;30(3):297-302. doi: 10.1111/jon.12694. Epub 2020 Feb 10. PMID: 32037621; PMCID: PMC7321834.
114. Reich H, Ramzy D, **Moriguchi J**, Dimbil S, Levine R, Passano E, Kittleson M, Cole R, Czer L, Chang D, Geft D, Trento A, Chikwe J, Kobashigawa J, Esmailian F. Acceptable Post-Heart Transplant Outcomes Support Temporary MCS Prioritization in the New OPTN|UNOS Heart Allocation Policy. *Transplant Proc*. 2020 Jul 7:S0041-1345(19)31498-8. doi: 10.1016/j.transproceed.2020.04.1819. Online ahead of print. PMID: 32650992.
115. Zadikany RH, Cole RM, Chang DH, Patel JK, Geft DR, Czer L, Esmailian F, Ramzy D, **Moriguchi JD**, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Retransplantation. *ASAIO J*. 2020 Jun 29;10.1097/MAT.0000000000001217. doi: 10.1097/MAT.0000000000001217. Online ahead of print. PMID: 32639257.
116. Kittleson MM, Barone H, Cole RM, Olman M, Fishman A, Olanisa L, Runyan C, Hajj J, Huie N, Lindsay M, Sun N, Luong E, Cheng S, Passano E, Kobashigawa JA, Esmailian F, Ramzy D, **Moriguchi JD**. The Impact of a High-risk Psychosocial Assessment on Outcomes After Durable Mechanical Circulatory Support. *ASAIO J* 2020 Jul 23. doi: 10.1097/MAT.0000000000001229. Online ahead of print.

117. Carrier M, **Moriguchi J** et al Outcomes after heart transplantation and total artificial heart implantation: A multicenter study *Journal of Heart and Lung Transplantation* Art in press. Pub 11/27/20  
Jhealun.2020.11.012
118. Chen Q, **Moriguchi J**, Levine R, Chan J, Dimbil S, Patel J, Kittleson M, MegnaD, Emerson D, Ramzy D, Trento A, Chikwe J, Kobashigawa J, Esmailian F. Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. *Transplant Proc.* 2021 Jan-Feb;53(1):329-334. doi:10.1016/j.transproceed.2020.08.020. Epub 2020 Sep 8. PMID: 32917391.
119. Zadikany RH, Cole RM, Chang DH, Patel JK, Geft DR, Czer L, Esmailian F, Ramzy D, **Moriguchi JD**, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Retransplantation. *ASAIO J.* 2021 Mar 1;67(3):e77-e79. doi: 10.1097/MAT.0000000000001217. PMID: 33627614; PMCID: PMC7326319.
120. Carrier M, **Moriguchi J**, Shah KB, Anyanwu AC, Mahr C, Skipper E, Cossette M, Noly PE. Outcomes after heart transplantation and total artificial heart implantation: A multicenter study. *J Heart Lung Transplant.* 2021 Mar;40(3):220-228. doi: 10.1016/j.healun.2020.11.012. Epub 2020 Nov 28. PMID: 33341359.
121. Kittleson MM, Barone H, Cole RM, Olman M, Fishman A, Olanisa L, Runyan C, Hajj J, Huie N, Lindsay M, Sun N, Luong E, Cheng S, Passano E, Kobashigawa JA, Esmailian F, Ramzy D, **Moriguchi JD**. The Impact of a High-risk Psychosocial Assessment on Outcomes After Durable Mechanical Circulatory Support. *ASAIO J.* 2021 Apr 1;67(4):436-442. doi: 10.1097/MAT.0000000000001229. PMID: 32740124.

**Research Papers – Peer Reviewed (In Press): None**

**Research Papers – Peer Reviewed (Submitted): None**

**Chapters:**

1. Stevenson LW, **Moriguchi J**, Child JS. Echocardiography in Cardiac Transplantation, in *Cardiac Imaging*, ed O'Rourke, Little, Brown & Co., Boston, in press.
2. Martin SM, Laks H, Drinkwater DC, Stevenson LW, Kawata N, Kobashigawa JA, **Moriguchi JD**, Hamilton MA. Cardiac Transplantation: The UCLA Experience 1984 to 1990. In: Terasaki P, ed. *Clinical Transplantation 1990*. Los Angeles, CA: The Regents of the University of California, 1991:103-114.
3. Ardehali A, Laks H, Drinkwater DC, Ziv ET, Sorensen TJ, Hamilton MA, Stevenson LW, **Moriguchi JD**, Kobashigawa JA. Cardiac Transplantation at UCLA. In: Terasaki P, Cecka JM, eds. *Clinical Transplants 1993*. Los Angeles, CA: The Regents of the University of California, 1994:119-128.
4. Kobashigawa JA, Laks H, Drinkwater DC, **Moriguchi J**, Hamilton M, Hage A, Blitz A, Kawata N. The University of California at Los Angeles Experience in Heart Transplantation, in Terasaki P, Cecka JM, eds. *Clinical Transplants 1995*. Los Angeles, CA. The Regents of the University of California, 1996.
5. Kobashigawa JA, Laks H, Marelli D, **Moriguchi JD**, Hamilton MA, Fonarow G, Hage A, Kawata N. The University of California at Los Angeles Experience in Heart Transplantation. In: Terasaki P, Cecka JM, eds. *Clinical Transplants 1998*. Los Angeles, CA: The Regents of the University of California, 1998.



6. Kobashigawa JA, Laks H, Wu G, Patel J, **Moriguchi J**, Hamilton M, Fonarow G, Fishbein M, Ardehali A. The University of California at Los Angeles heart transplantation experience. *Clin Transpl.* 2005;173-85.
7. Arabia FA, **Moriguchi JD** “Machines versus medication for biventricular heart failure: focus on the total artificial heart” in *Future Cardiology* (2014) 10(5), 593-609.
8. Moriguchi, JD “Mechanical and Surgical Options for Patients with End-Stage Heart Failure” in *Clinical Guide to Heart Transplantation*. Editor: Jon Kobashigawa Springer 2017 Chapter 2 p11-19.

**Chapters: In Press: None**

**Letters:**

1. Cheng R, Esmailian F, **Moriguchi J**. On the Edge of a Precipice: A Bridge to Options for Patients with End-Stage Heart Failure and Cardiogenic Shock. *ASAIO J.* 2020 Jan 21. doi: 10.1097/MAT.0000000000001116. No abstract available. PMID: 31977353

**Reviews: None**

**Editorials: None**

**Papers in Preparation (Research Completed): None**

**Abstracts:**

1. **Moriguchi JD**, Stevenson LW, Kobashigawa JA, Westlake C, Kawata N. Cardiac Transplant Rejection Causes Decreased Systolic Function Which Can Be Detected Echocardiographically. *Clinical Research* 36:111A, 1988.
2. **Moriguchi JD**, Stevenson LW, Kobashigawa JA, Westlake C, Laks H, Child JS. Decrease in 2-dimensional Echocardiographic Ejection Fraction During Transplant Rejection: A Study of 400 Biopsies. *J Am Coll Cardiol*, 11:121A, 1988.
3. Kobashigawa JA, Stevenson LW, **Moriguchi JD**, Westlake C, Kawata N, Drinkwater D, Laks H. A Randomized Study of High-dose Cyclosporin for Mild Acute Rejection. *Journal of Heart Transplantation* 7:84, 1988.
4. Walden JA, Stevenson LW, Dracup KA, Wilmarth J, Kobashigawa J, **Moriguchi J**. Cardiac Transplantation May Not Improve Quality of Life for Patients with Stable Heart Failure. *Circulation* 78: II-217, 1988.
5. Luu M, Stevenson LW, Tillisch JH, **Moriguchi J**, Walden J. Revised Medical Therapy Frequently Achieves Hemodynamic Goals in Heart Failure After Referral for Cardiac Transplantation. *Clin Res* 37:97A, 1989.
6. Stevenson LW, **Moriguchi JD**, Kobashigawa JA, Tillisch JH, Walden JA, Drinkwater DC, Laks H. Decreasing Survival Benefit of Cardiac Transplantation as Waiting List Lengthens. *Circulation* 80: II-671, 1989.

7. Stevenson LW, Hamilton MA, **Moriguchi JD**, Tillisch JH, Walden JA. Good Survival Despite Ejection Fraction  $\leq$  20%: Importance of Achieving Low Filling Pressures During Therapy. *Circulation* 180: II-671, 1989.
8. Kobashigawa JA, Murphy F, Stevenson LW, **Moriguchi JD**, Kawata N, Chuck C, Wilmarth J, Leonard L, Drinkwater D, Laks H. Low Dose of Lovastatin Safely Lowers Cholesterol after Cardiac Transplantation. *Circulation* 80: \*\*-641, 1989.
9. Chelimsky-Fallick C, Stevenson LW, **Moriguchi JD**, Walden JA, Lem V. Six Minute Walk Identifies Advance Heart Failure Patients with Poor Prognosis. *J Am Coll Cardiol* 15:251A, 1990.
10. Chelimsky-Fallick C, Luu M, Stevenson LW, Hamilton M, **Moriguchi J**, Tillisch J, Walden D. Hydralazine Rescue in Hyponatremic Heart Failure. *Clin Res* 38:86A, 1990.
11. Chelimsky-Fallick C, Stevenson LW, **Moriguchi J**, Walden J, Lem V. Short Distance During Six Minute Walk Identifies Heart Failure Patients with Low Peak Oxygen Consumption. *Clin Res* 38:86A, 1990.
12. Stevenson LW, Chelimsky-Fallick C, Tillisch J, **Moriguchi J**, Kobashigawa J, Milgalter E, Drinkwater D, Laks H. Unacceptable Risk of Sudden Death without Transplantation if Low Ejection Fraction is Due to Coronary Artery Disease. *J Am Coll Cardiol* 15:222A, 1990.
13. Kobashigawa J, Stevenson L, **Moriguchi J**, et al. Is an Intravenous Glucocorticoid Pulse Better than Oral Taper for Asymptomatic Cardiac Rejection? A Randomized Trial. Abstract presented at the *American College of Cardiology Scientific Session* in March 1990.
14. Kobashigawa J, Stevenson L, **Moriguchi J**, et al. Influenza Vaccine Does Not Cause Rejection After Cardiac Transplantation. Abstract presented at the *American College of Cardiology Scientific Session* in March 1990.
15. Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, **Moriguchi J**, Tillisch JH, Walden JA. Hydralazine Rescue in Advanced Heart Failure Patients with Hyponatremia. *Clin Res*, 38, 1990.
16. Walden JA, Dracup K, Hamilton MA, Chelimsky-Fallick C, **Moriguchi J**. Quality of Life in Advanced Heart Failure. *Circulation*, 82: III-705, 1990.
17. Fonarow G, Chelimsky-Fallick C, Stevenson LW, Stevenson WG, Luu M, Hamilton MA, **Moriguchi J**, Walden JA, Tillisch J. Impact of Vasodilator Regimen on Sudden Death in Advanced Heart Failure: A Randomized Trial of Angiotensin-Converting-Enzyme Inhibition and Direct Vasodilation. *J Am Coll Cardiol*, 17:92A, 1991.
18. Fonarow G, Chelimsky-Fallick C, Steven LW, Luu M, Hamilton MA, **Moriguchi J**, Walden JA, Albanese E, Tillisch J. Survival with Angiotensin-Converting-Enzyme Inhibition vs. Direct Vasodilation for the Same Hemodynamic Goals in Advanced Heart Failure: 106 Randomized Patients. *J Am Coll Cardiol*, 17:274A, 1991.
19. Kobashigawa J, Stevenson LW, Louie H, Imagawa D, **Moriguchi J**, Kawata N, Drinkwater D, Laks H. Elevated Serum Tumor Necrosis Factor in not Useful for Monitoring Cardiac Transplant Rejection. *J Am Coll Cardiol*, 17, 1991.

20. Kobashigawa J, Stevenson LW, Brownfield E, Louie H, **Moriguchi J**, Kawata N, Leonard L, Fandrich R, Sheehan P, Drinkwater D, Laks H. Outcome of ABO Compatible Versus Identical Blood Type Matching in Cardiac Transplant Recipients on Triple Immunotherapy. *J Am Coll Cardiol*, 17:309A, 1991.
21. Chelimsky-Fallick C, Kobashigawa J, Stevenson WG, Middlekauff H, Brownfield E, **Moriguchi J**, Hamilton M, Drinkwater D, Laks H, Stevenson LW. Chronic Amiodarone Therapy Prior to Cardiac Transplantation Does Not Increase the Peri-Operative Risk. *J Am Coll Cardiol*, 17:290A, 1991.
22. Kobashigawa J, Stevenson L, **Moriguchi J**, et al. A randomized trial of short course OKT3 induction vs. initial triple therapy: Impact on rejection and renal function after cardiac transplantation. *J Heart Transplant*, 10:163, 1991.
23. Kobashigawa J, Stevenson L, **Moriguchi J**, et al. Lack of appropriate erythropoietin response in anemia after cardiac transplantation. *J Heart Lung Transplant*, 10:178, 1991.
24. Kobashigawa J, Stevenson L, **Moriguchi J**, et al. Inadequate erythropoietin production in cardiac transplant patients with anemia. *J Am Coll Cardiol*, 17:364A, 1991.
25. Fonarow GC, Chelimsky-Fallick C, Hamilton MA, **Moriguchi JD**, Kobashigawa JA, Walden JA, Tillisch JH, Stevenson LW. Medical therapy has improved to rival cardiac transplantation for advanced heart failure *Circulation*, Nov 1992.
26. Kobashigawa JA, Brownfield ED, Stevenson LW, Gleeson MP, **Moriguchi JD**, Kawata N, Hamilton MA, Hage AS, Minkley R, Salamandra J, Ruzevich. Effects of pravastatin in cardiac transplant recipients. *J Am Coll Cardiol*, 21:141A, 1993.
27. J. Kobashigawa, L. Stevenson, **J. Moriguchi**, N. Kawata, E. Brownfield, D. Drinkwater, H. Laks. Is Intravenous Glucocorticoid Therapy Better Than an Oral Regimen for Asymptomatic Cardiac Rejection? A Randomized Trial. *J Am Coll Cardiol*; 21:5, 1993.
28. Kobashigawa JA, Gleeson MP, Stevenson LW, **Moriguchi JD**, Kawata N, Hage AS, Hamilton MA, Drinkwater DC, Laks H. Significance of mild rejection late after cardiac transplant in patients with and without steroid maintenance. *J Am Coll Cardiol*, 21:36A, 1993.
29. Kobashigawa JA, Brownfield ED, Stevenson LW, **Moriguchi JD**, Hamilton MA, Hage AS, Kawata N, Minkley R, Salamandra J, Ruzevich S, Drinkwater DC, Laks H. Hypercholesterolemia in the first year post cardiac transplant is related to transplant coronary arteriopathy despite subsequent lowering. *J Am Coll Cardiol*, 21:169A, 1993
30. Kobashigawa JA, Gleeson MP, Stevenson LW, Brownfield ED, **Moriguchi JD**, Kawata N, Hage A, Hamilton MA, Drinkwater DC, Laks H. Benefit of steroid weaning late after cardiac transplant: Relationship to transplant coronary artery disease. *J Am Coll Cardiol*, 230A, 1994
31. Kobashigawa JA, Leaf DA, Gleeson MP, Hamilton MA, Chelimsky-Fallick C, **Moriguchi JD**, Kawata N, Skotzko C, Herlihy E, Lee N, Stevenson LW. A randomized study of cardiac rehabilitation in heart transplant recipients. *J Am Coll Cardiol*, 356A, 1994.
32. Gleeson MP, Kobashigawa JA, Stevenson LW, **Moriguchi JD**, Kawata N, Hamilton MA, Hage A, Drinkwater DC, Laks H. The natural history of focal moderate rejection in orthotopic heart transplant recipients. *J Am Coll Cardiol*, 483A, 1994.

33. Kobashigawa JA, Gleeson MP, Stevenson LW, Carr JG, **Moriguchi JD**, Kawata N, Hamilton MA, Hage A, Drinkwater DC, Laks H. Prevention of severe cardiac allograft rejection with pravastatin: A randomized trial. *J Am Coll Cardiol*, 483A, 1994.
34. **Moriguchi J**, Gleeson MP, Rich D, Kobashigawa JA, et al. The Natural History of Focal Moderate and Mild Diffuse Rejection. Presented at *American College of Cardiology*, Atlanta, Georgia, 3/94.
35. Kobashigawa JA, Gleeson MP, Hamilton MA, **Moriguchi JD**, Kawata N, Hage A, Drinkwater D, Laks H. Survivors of cardiac transplant rejection with hemodynamic compromise appear to be at increased risk to develop transplant coronary artery disease. *American Society of Transplant Physicians Scientific Sessions*, May 16, 1994, Chicago, IL.
36. Kobashigawa JA, Gleeson MP, Hamilton MA, **Moriguchi JD**, Kawata N, Hage A, Drinkwater D, Laks H. When to consider cardiac retransplantation in patients who develop transplant coronary artery disease. *American Society of Transplant Physicians Scientific Sessions*, May 16, 1994, Chicago, IL.
37. Ardehali A, Laks H, Drinkwater DC, Kobashigawa J, **Moriguchi J**, Drake TA. Vascular cell adhesion molecule-1 upregulation precedes and predicts cellular rejection of human cardiac allografts. *American College of Surgeons*, October 12, 1994, Chicago, IL.
38. Kobashigawa JA, Gleeson MP, Laks H, **Moriguchi J**, Kawata N, Hamilton M, Hage A, Drinkwater D. Long term outcome of mono-immunosuppression in cardiac transplant recipients. *J Am Coll Cardiol*, February 1995: 242A.
39. Kobashigawa JA, Sabad A, Cogert GA, Kawata N, **Moriguchi JD**, Hamilton MA, Hage A, Drinkwater D, Laks H. Mild-moderate obesity after cardiac transplant is not associated with transplant coronary artery disease or poor outcome. *American Society of Transplant Physicians*, May 1995:142.
40. Kobashigawa JA, Sabad A, Cogert G, **Moriguchi JD**, Kawata N, Hamilton MA, Hage A, Drinkwater D, Laks H. Panel reactive antibodies: Are they truly a marker for poor outcome? *Circulation* 1995; 92:1-125.
41. Kobashigawa JA, **Moriguchi JD**, Laks H, Hamilton MA, Hage A, Kawata N, Sabad A, Cogert GC, Muhlmeister HF, Drinkwater DC. Successful therapy for cardiac transplant recipients with hemodynamic compromising rejection. *Circulation* 1996;94(8): I-479.
42. "Risk Factors for Sudden Death While Awaiting Transplantation," Scientific Sessions of the International Society of Heart and Lung Transplantation, London, England. April 1997.
43. Kobashigawa JA, Cogert GA, Sabad A, Muhlmeister H, Cassem JD, **Moriguchi J**, Kawata N, Hamilton MA, Hage A, Drinkwater D, Laks H. Naturally occurring leukopenia as a marker for good outcome after cardiac transplantation. *J Am Coll Cardiol* 1997;29(2A):28A.
44. Kobashigawa JA, Johnson J, **Moriguchi JD**, Sabad A, Wener L, Cogert GA, Hage A, Hamilton M, Kawata N, Drinkwater D, Laks H. Obesity as a risk factor for transplant coronary artery disease: The IVUS truth. *J Am Coll Cardiol* 1997;29(2A):291A.
45. Kobashigawa JA, **Moriguchi JD**, Sabad A, Albanese E, Cogert GA, Hamilton MA, Hage A, Kawata N, Cassem JD, Liu H, Drinkwater D, Laks H. Cyclosporine and pravastatin pharmacokinetics in cardiac transplant recipients. *J Heart and Lung Transplant* 1997; 16:84.

46. **Moriguchi JD**, Kobashigawa JA, Sabad A, Hamilton MA, Hage A, Kawata N, Cogert GA, Cassem JD, Muhlmeister H, Drinkwater D, Laks H. Estrogen therapy in postmenopausal heart transplant women may be effective in cholesterol lowering. *J Heart and Lung Transplant* 1997;16:84.
47. Kobashigawa JA, **Moriguchi JD**, Russell SD, Einhorn K, Ro TK, English JA, Cassem JD, Kawata N, Laks H. Early results of FK506 versus Neoral: a randomized trial. *The International Congress on Immunosuppression*, Orlando, FL, December 13, 1997.
48. Wener LS, **Moriguchi JD**, Kawata N, Hage A, Hamilton MA, Einhorn K, English JA, Cassem JD, Kobashigawa JA. Redo heart transplant patients are at risk for first year increased intimal thickening by coronary ultrasound. *Circulation* 1997;96(8): I-369.
49. Kobashigawa JA, **Moriguchi JD**, Ro TK, Einhorn K, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Atorvastatin for refractory hypercholesterolemia in heart transplant patients. *J Am Coll Cardiol* 1998;31: 157A.
50. Kobashigawa JA, Einhorn K, Ro TK, Cassem JD, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Laks H. The meaning of mild rejection in steroid-free heart transplant recipients. *J Am Coll Cardiol* 1998;31: 35A.
51. Wang XM, Kobashigawa JA, Terasaki PI, **Moriguchi JD**, Einhorn K, Laks H. Pravastatin reduces natural killer cell cytotoxicity in heart transplant patients on FK506. *J Heart Lung Transplant* 1998;17: 57.
52. Kobashigawa JA, Einhorn K, Ro TK, Cassem J, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Laks H. Mild rejection in steroid-free heart transplant recipients: Is it of concern? *J Heart Lung Transplant* 1998;17: 84.
53. Kobashigawa JA, **Moriguchi JD**, Ro TK, Einhorn K, Cassem J, Hamilton MA, Hage A, Kawata N, Laks H. Refractory hypercholesterolemia in heart transplant patients: response to atorvastatin. *J Heart Lung Transplant* 17: 107.
54. Kobashigawa JA, Ro TK, Einhorn K, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Laks H. Increased morbidity in insulin-dependent diabetic patients long-term after heart transplantation. *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.
55. Kobashigawa JA, Ro TK, Einhorn K, Cogert GA, Cassem JD, **Moriguchi JD**, Kawata N, Hamilton MA, Hage A, Laks H. Risk factors for malignancies in heart transplant recipients. *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.
56. Kobashigawa JA, Einhorn K, **Moriguchi JD**, Cassem JD, Ro TK, Hamilton MA, Hage A, Kawata N, Laks H. The meaning of mild rejection during corticosteroid weaning in heart transplant recipients. *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.
57. Kobashigawa JA, Fishbein M, English JA, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Laks H. Quilty B lesions on endomyocardial biopsies: are they associated with subsequent histologic rejection in cardiac transplant patients? *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.
58. **Moriguchi JD**, Kobashigawa JA, Ro TK, Einhorn K, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. At what creatinine level is angiographic dye safe for coronary angiography in cardiac transplant recipients? *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.

59. Kobashigawa JA, Ro TK, **Moriguchi JD**, Cassem JD, English JA, Einhorn K, Cogert GA, Hamilton MA, Hage A, Kawata N, Laks H. Cholesterol lowering after heart transplantation is associated with a lower incidence of transplant coronary artery disease. *ASTP Scientific Sessions*, Chicago Sheraton Hotel, May 9-13, 1998.
60. Kobashigawa JA, Lin P, **Moriguchi JD**, Ro TK, Cassem JD, Hamilton MA, Hage A, Kawata N. Do Heart Transplant Patients on Corticosteroid-Free Immunosuppression Have Less Rejection? *Circulation* 1999;100(18): I-525.
60. Kobashigawa JA, Ro TK, Chuang J, **Moriguchi JD**, Schiller G, Kawata N. The Use of Photopheresis for the Treatment of Chronic Humoral Rejection in Heart Transplant Patients. *Circulation* 1999;100(18): I-526.
61. Kobashigawa JA, Ro TK, Einhorn K, **Moriguchi JD**, Hamilton MA, Hage A, Kawata N, Cassem JD, Laks H. Redo heart transplants have increased incidence of transplant coronary artery disease: impact on long-term survival. *J Am Coll Cardiol* 1999.
62. J.A. Kobashigawa, **J.D. Moriguchi**, H. Laks, T.K. Ro, M.A. Hamilton, A. Hage, L. Wener, N. Kawata. Five-year follow-up of a randomized trial of pravastatin in heart transplant patients. *J Heart Lung Transplant* 1999.
63. **J.D. Moriguchi**, J.A. Kobashigawa, T.K. Ro, M.A. Hamilton, A. Hage, N. Kawata, H. Laks. Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients. *J Heart Lung Transplant* 1999; 18:28.
64. J Chait, J Kobashigawa, J Chuang, **J Moriguchi**, N Kawata, H Laks. Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients. *J Heart Lung Transplant* 1999; 18:20.
65. Kobashigawa JA, Ro TK, **Moriguchi JD**, Lee R, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients. *J Heart Lung Transplant* 1999; 18:16.
66. D Marelli, H Laks, D Fazio, S Moore, **J Moriguchi**, J Kobashigawa. The Use of Donor Hearts with Left Ventricular Hypertrophy. *J Heart Lung Transplant* 1999.
67. Invited Speaker, International Society for Heart and Lung Transplantation: Long Term Effects of Medical Insurance on Heart Transplant Recipients. Osaka International Convention Center, Osaka, Japan, April 2000.
68. Invited Speaker, International Society for Heart and Lung Transplantation: A Pilot Study of L-Arginine for Renal Insufficiency in Heart Transplant Recipients. Osaka International Convention Center, Osaka, Japan, April 2000.
69. Invited Speaker, International Society for Heart and Lung Transplantation: Development of Circulating IgG Class I Antibodies is Associated With Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) After Heart Transplant. Osaka International Convention Center, Osaka, Japan, April 2000.
70. Kobashigawa JA, **Moriguchi JD**, Chuang JM, et al. A randomized trial of tacrolimus versus neoral cyclosporine in heart transplant recipients. *J Am Coll Cardiol* 2000;35:222A.

71. Kobashigawa JA, Devereaux D, **Moriguchi JD**, et al. Effect of race in outcomes after heart transplantation. *J Am Coll Cardiol* 2000;35:167A.
72. Kobashigawa JA, **Moriguchi JD**, Takemoto S, Chuang JM, Wener L, Yeatman L, Ro T, Devereaux D, Kawata N, Laks H. First Year Results of a Randomized Trial of Tacrolimus vs. Neoral Cyclosporine in Heart Transplant Patients. *J Heart Lung Transplant* 2000.
73. H. Laks, D. Marelli, D. Fazio, A. Sadeghi, A. Ardehali, M. Hamilton, **J. Moriguchi**, G. Fonarow, A. Hage, F. Esmailian, N. Kawata, J. Kobashigawa. Intermediate Term Results of the Alternate Recipient List for Heart Transplantation. *J Heart Lung Transplant* 2000.
74. D. Marelli, H. Laks, D. Fazio, A. Sadeghi, A. Ardehali, **J. Moriguchi**, E. Houston, M. Talamo, F. Esmailian, A. Hage, M. Hamilton, G. Fonarow, N. Kawata, J. Kobashigawa. The Use of Marginal Donor Hearts. *J Heart Lung Transplant* 2000.
75. **J.D. Moriguchi**, J.A. Kobashigawa, S. Takemoto, L. Wener, J. Tobis, R. Lee, N. Kumar, J.M. Chuang, N. Kawata, H. Laks. Development of Circulating IgG Class I Antibodies is Associated With Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) After Heart Transplant. *J Heart Lung Transplant* 2000.
76. R. Camara, J.A. Kobashigawa, S. Lackey, J.M. Chuang, **J.D. Moriguchi**, N. Kawata, H. Laks. Concern Regarding the Use of Orlistat (Xenical) For the Treatment of Obesity in Cardiac Transplant Recipients. *J Heart Lung Transplant* 2000.
77. **J.D. Moriguchi**, P. Bueno, J.A. Kobashigawa, J.M. Chuang, S. Lackey, R. Camara, N. Kawata, H. Laks. A Pilot Study of L-Arginine for Renal Insufficiency in Heart Transplant Recipients. *J Heart Lung Transplant* 2000.
78. J.M. Chuang, J.A. Kobashigawa, M. Mui, S. Lackey, R. Camara, **J.D. Moriguchi**, N. Kawata, M. Marks, A. Velleca, M. Brown, H. Laks. What are the Infectious Risks of Pets Immediately After Heart Transplant? *J Heart Lung Transplant* 2000.
79. **J.D. Moriguchi**, D. Devereaux, J.A. Kobashigawa, S. Lackey, R. Camara, A. Velleca, M. Marks, M. Brown, J.M. Chuang, N. Kawata, H. Laks. Long Term Effects of Medical Insurance on Heart Transplant Recipients. *J Heart Lung Transplant* 2000.
80. D Marelli, H Laks, **J Moriguchi**, D Fazio, M Hamilton, G Fonarow, A Hage, S Salehmoghaddam, B Kubak, D Meehan, M Talamo, A Sadeghi, F Esmailian, A Ardehali, M Plunkett, J Kobashigawa. Single Institution Outcome Analysis of 344 Consecutive Patients Receiving Donor Hearts Preserved Using University of Wisconsin Solution. *AST Chicago*, Chicago Sheraton Hotel, May 15, 2000.
81. Daniel Marelli, Michele A. Hamilton, Hillel Laks, Gregg C Fonarow, Daniel Fazio, **Jaime D. Moriguchi**, Saleh Saleh, Bernard Kubak, Abbas Ardehali, Fardad Esmailian, Antoine Hage, Jon A. Kobashigawa. Heart Transplantation in the Elderly. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. *Circulation* 2000;102: II-490.
82. Daniel Marelli, Hillel Laks, Daniel Fazio, **Jaime D. Moriguchi**, Gregg C. Fonarow, Saleh Salehmoghaddam, Bernard Kubak, Juan C. Alejos, Alvaro Galindo, Jon A. Kobashigawa. Clinical and Laboratory Studies in Thoracic Organ Transplantation. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. *Circulation* 2000;102: II-763.

83. G. Giesler, M. Espejo, B. Kubak, **J. Moriguchi**, J. Patel, H. Laks, J. Kobashigawa. Increased Risk of CMV Infection in Heart Transplant Patient on Mycophenolate Mofetil. *J Heart Lung Transplant* 2001; 20: 178.
84. K Shivkumar, M Espejo, J Kobashigawa, M Watanabe, M Ikeda, J Chuang, J Patel, **J Moriguchi**, M Hamilton, N Kawata, H Laks. Sudden Death After Heart Transplantation: The Major Mode of Death. *J Heart Lung Transplant* 2001; 20: 180.
85. M. Espejo, J. Kobashigawa, **J. Moriguchi**, J. Patel, N. Kumar, M. Hamilton, A. Hage, N. Kawata, H. Laks. The Dilemma of Disability After Heart Transplantation. *J Heart Lung Transplant* 2001; 20: 244.
86. D. Marelli, F. Tsai, H. Laks, E. Houston, J. Bresson, L. Friend, D. Gjertson, A. Sykes, A. Ardehali, F. Esmailian, M. Hamilton, G. Fonarow, **J. Moriguchi**, M. Plinkett, A. Hage, M. Brown, M. Mark, J. Kobashigawa. Use of Heart Transplanted from Donors with Atraumatic Intracranial Bleeds. *J Heart Lung Transplant* 2001; 20: 256.
87. G. Cogert, Jon Kobashigawa, M. Espejo, J. Patel, **J. Moriguchi**, H. Laks. Plasmapheresis Lowers the Incidence of Transplant Coronary Artery Disease following Hemodynamic Transplant Rejection. *AST Chicago*, Chicago Sheraton Hotel, May 15, 2001.
88. ISHLT mini-oral presentation in Washington, D.C. The Decreasing Incidence of Cardiac Allograft Rejection and Its Impact on Clinical Trials **J Moriguchi**, S Subherwal, M Espejo, MC Fishbein, J Patel, H Laks, J Kobashigawa University of California, Los Angeles, California, April 2002.
89. H. Middlekauff, K. Hui, J. Liang Yu, M. Hamilton, G. Fonarow, **J. Moriguchi**, W. Robb Maclellan, A. Hage. Acupuncture Inhibits Sympathetic Activation During Mental Stress in Advanced Heart Failure Patients. *Journal of Cardiac Failure*; 8:6, 2002.
90. J. Kao, **J. Moriguchi**, A. Ardehali, K. Shannon, N. Boyle. Use of a Donor Heart with Symptomatic WPW in an Alternate Donor Program. *J. Heart Lung Transplant*; 21:12, 2002.
91. J. Kobashigawa, L. Stevenson, **J. Moriguchi**, N. Kawata, E. Brownfield, D. Drinkwater, H. Laks. Is Intravenous Glucocorticoid Therapy Better Than an Oral Regimen for Asymptomatic Cardiac Rejection? A Randomized Trial. *J A Coll Cardiol*; 21:5
92. Cruz D, Espejo Vassilakis M, Garfinkel A, **Moriguchi J**, Fonarow G, Fishbein M, Kobashigawa J, Patel J. The vagrancy of B-type natriuretic peptide (BNP) levels in orthotopic heart transplant (OHT) recipients. Presented at *American College of Cardiology Scientific Session*, Chicago, IL, April 2003.
93. Cole BT, Kobashigawa JA, Patel JP, **Moriguchi J**, Espejo Vassilakis M, Go SE, Chait J, Laks H. Perception is deceiving; the real gender specific exercise capacity of heart transplant recipients. Accepted for presentation at *International Society for Heart and Lung Transplantation Annual Meeting*, Vienna, Austria, April 2003.
94. GA Cogert MD, S Subherwal BS, G Wu, JK Patel MD PhD, M Espejo Vassilakis BA, MC Fishbein MD, **J Moriguchi** MD, H Laks MD, and JA Kobashigawa MD. Incidence of Non-Cellular (Humoral) Rejection Unchanged in the 1990 Decade Despite a Decrease in Cellular Rejection. Accepted for presentation at *International Society for Heart and Lung Transplantation Annual Meeting*, Vienna, Austria, April 2003.



95. M Espejo Vassilakis BA, JA Kobashigawa MD, S Subherwal BS, MC Fishbein MD, JK Patel MD PhD, **J Moriguchi** MD, S Go, P Almeda and H Laks MD. Scoring of 2.788 Endomyocardial Biopsies Correlate Rejection to the Development of Transplant Coronary Artery Disease After Heart Transplantation. Accepted for presentation at *International Society for Heart and Lung Transplantation Annual Meeting*, Vienna, Austria, April 2003.
96. GA Cogert MD, K Shivkumar MD PhD, JK Patel MD PhD, I Weiner MD, **J Moriguchi** MD, M Espejo Vassilakis BA, H Laks MD, and JA Kobashigawa MD. Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death: Shocking News? Accepted for presentation at *International Society for Heart and Lung Transplantation Annual Meeting*, Vienna, Austria, April 2003.
97. Kobashigawa JA, Takano Y, Tobis JM, Cogert, G, Espejo Vassilakis M, **Moriguchi J**, Laks H. A randomized trial switching from azathioprine to mycophenolate mofetil in cardiac transplant patients with newly diagnosed angiographic transplant coronary artery disease. Accepted for presentation at *American Transplant Congress*, Washington DC, June 2003.
98. Kobashigawa JA, Cogert GA, Tobis JM, Currier J, Espejo Vassilakis M, Patel JK, **Moriguchi JD**, Laks H. Improved survival of heart transplant patients with severe transplant coronary artery disease in the era of percutaneous coronary intervention and statin therapy. Accepted for presentation at *American Transplant Congress*, Washington DC, June 2003.
99. Ji S, Cesario D, Valderrabano M, Cote S, Hardie M, Boyle NG, Shannon KM, Espejo-Vassilakis M, Hamilton MA, Hage A, **Moriguchi JD**, Patel JK, Kobashigawa JA, Wiener I, Shivkumar K, UCLA Cardiac Arrhythmia Center, Los Angeles, CA. Mechanistic Basis of Supraventricular Arrhythmias Following Orthotopic Cardiac Transplantation. Accepted for presentation at *American Heart Association Conference 2003*, Orlando, FL, November 9-11, 2003.
100. Cui G, Fonarow G, Kobashigawa JA, Hamilton M, **Moriguchi J**, Sen L; UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA. Genotype-Phenotype Correlation of RYR2 Gene Mutations in Inherited Idiopathic Dilated Cardiomyopathy. Accepted for presentation at *American Heart Association Conference 2003*, Orlando, FL, November 9-11, 2003.
101. Kobashigawa JA, Patel JK, Marquez A, Oeser BT, **Moriguchi JD**, Laks H, University of California, Los Angeles, Los Angeles, CA. The Renal Benefit of Calcinerin Inhibitor-Free Immunosuppression After Heart Transplantation: Is it Safe? Accepted for presentation at *American College of Cardiology 53rd Annual Scientific Sessions 2004*, New Orleans, LA, March 8, 2004.
102. JA Kobashigawa MD, JK Patel MD, PhD, A Marquez BA, BT Oeser MPH, **JD Moriguchi** MD, H Laks MD, University of California at Los Angeles. The Renal Benefit of Calcineurin Inhibitor-Free Immunosuppression After Heart Transplantation: Is it Safe? Accepted for presentation at the *American College of Cardiology 53<sup>rd</sup> Annual Scientific Sessions*, New Orleans, LA, March 7-10, 2004.
103. J A Kobashigawa, MD <sup>1</sup>, J D Moriguchi, MD <sup>1</sup>, J Patel, MD, PhD. <sup>1</sup>, J Shaw, BS <sup>1</sup>, B T Oeser, MPH <sup>1</sup> and H Laks, MD <sup>1</sup>. <sup>1</sup> University of California at Los Angeles, Los Angeles, CA. Five-Year Results of a Randomized Single Center Study of Tacrolimus (TAC) vs. Neoral Cyclosporine (CYA). Accepted for presentation at the *International Society for Heart and Lung Transplantation Conference 2004*, San Francisco, CA, April 2004.
104. J A Kobashigawa, MD <sup>1</sup>, J D Moriguchi, MD <sup>1</sup>, G Cogert, MD <sup>1</sup>, A Hage, MD <sup>1</sup>, M A Hamilton, MD <sup>1</sup>, M E Vassilakis, BA <sup>1</sup>, A Marquez, BA <sup>1</sup>, L Yeatman, MD <sup>1</sup>, J Patel, MD <sup>1</sup> and H Laks, MD <sup>1</sup>. <sup>1</sup> Division of Cardiology, University of California at Los Angeles, Los Angeles, CA. 10-Year Results of the Pravastatin

Randomized Trial in Heart Transplant Recipients. Accepted for presentation at the *International Society for Heart and Lung Transplantation Conference 2004*, San Francisco, CA, April 2004.

105. J A Kobashigawa, MD <sup>1</sup>, G Cogert, MD <sup>1</sup>, J D Moriguchi, MD <sup>1</sup>, J K Patel, MD, PhD <sup>1</sup> and H Laks, MD <sup>2</sup>. <sup>1</sup> Division of Cardiology, University of California, Los Angeles, Los Angeles, CA and <sup>2</sup> Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA. The Highly Sensitized Patient Awaiting Heart Transplantation: Success with combination Therapy of Plasmapheresis and Intravenous Gamma Globulin. Accepted for presentation at the *International Society for Heart and Lung Transplantation Conference 2004*, San Francisco, CA, April 2004.
106. JK Patel, MD, PhD, BT Oeser, MPH, S Go, BS, BJ Rivera, BS, ML Plesa, BS, **JD Moriguchi**, MD, JA Kobashigawa. University of California at Los Angeles. Retransplantation – Never Too Old for One? Accepted for presentation at the *International Society for Heart and Lung Transplantation Conference 2004*, San Francisco, CA, April 2004.
107. Kobashigawa JA, Patel JK, Marquez A, Oeser BT, **Moriguchi JD**, Laks H, University of California, Los Angeles, Los Angeles, CA. The renal benefit of calcinerin inhibitor-free immunosuppression after heart transplantation: Is it safe? [abstract]. *J AM Coll Cardiol* 2004;43(5 SupplA):193A.
108. Kobashigawa JA, **Moriguchi JD**, Patel J, Shaw J, Oeser BT, and Laks H. Five-year results of a randomized single center study of tacrolimus (TAC) vs. neoral cyclosporine (CYA) [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl): S46.
109. Kobashigawa JA, Cogert G, **Moriguchi JD**, Patel JK, Laks H. The highly sensitized patient awaiting heart transplantation: success with combination therapy of plasmapheresis and intravenous gamma globulin [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1): S61.
110. Patel JK, Oeser BT, Go S, Rivera BJ, Plesa ML, **Moriguchi JD**, Kobashigawa JA. Retransplantation – never too old for one? [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1): S72.
111. Kobashigawa JA, **Moriguchi JD**, Cogert G, Hage A, Hamilton MA, Vassilakis ME, Marquez A, Yeatman L, Patel J, Laks H. 10-year results of the pravastatin randomized trial in heart transplant recipients [abstract]. *J Heart Lung Transplant* 2004;23(S Suppl 1): S115.
112. Patel JK, Nakashima J, **Moriguchi JD**, Oeser BT, Marquez A, Laks H, Kobashigawa JA. Poor outcome of early development of cardiac allograft vasculopathy after cardiac transplantation. Accepted for presentation at the *American Transplant Congress Annual Meeting 2004*, Boston, MA, May 15-19, 2004.
113. Mitropoulos FA, Laks H, Kermani R, Marelli D, Ardehali A, Plunkett M, Esmailian F, Odum J, **Moriguchi J**, Hamilton M, Patel J, Kobashigawa J. Use of donor hearts with left ventricular ejection fraction  $\leq 50\%$  for transplantation. Accepted for presentation at the *American Transplant Congress Annual Meeting 2004*, Boston, MA, May 15-19, 2004.
114. Patel JK, Mitropoulos F, Laks H, **Moriguchi JD**, Wang EZ, Oeser BT, Kobashigawa JA. Nesiritide immediately after heart transplantation: a pilot study [abstract]. *Am J Transplant* 2005;5(Suppl 11):169.
115. ISHLT mini-oral presentation in Paris, France. The Efficacy of Shorter Duration CMV Prophylaxis after Heart Transplantation April 2009

116. K Kiyosaki, J Kobashigawa, E Reed, **J Moriguchi**, M Kawano, A Ankrom, J Patel, M Kittleson, E Shao, A Ardehali. The Outcome of Treatment of 100% PRAs in Heart Failure Patients Awaiting Heart Transplantation. *J Heart Lung Transplant* 2009.
117. E Shao, M Kawano, K Kiyosaki, J Patel, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. Late Rapidly Progressive Cardiac Allograft Vasculopathy is Associated with Poor Outcome. *J Heart Lung Transplant* 2009.
118. J Patel, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. When is Too Old, Too Old for Redo Heart Transplantation? *J Heart Lung Transplant* 2009.
119. S Sohrabian, M Kawano, K Kiyosaki, A Ankrom, J Patel, **J Moriguchi**, M Kittleson, A Ardehali, J Kobashigawa. Spare Me the Renal Sparing Protocol - Poor Long-Term Outcomes. *J Heart Lung Transplant* 2009.
120. J Patel, M Kawano, K Kiyosaki, E Shao, A Ankrom, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. Addressing the Myth of Elevated Bilirubin as a Contraindication to Heart Transplantation. *J Heart Lung Transplant* 2009.
121. E Shao, M Kawano, J Patel, M Kittleson, A Ankrom, K Kiyosaki, **J Moriguchi**, A Ardehali, J Kobashigawa. The Problem of Rejection in Redo Heart Transplant Recipients. *J Heart Lung Transplant* 2009.
122. A Ankrom, J Patel, E Shao, S Carr, M Kawano, M Kittleson, K Kiyosaki, **J Moriguchi**, A Ardehali, J Kobashigawa. Obesity Confers Protection from Cardiac Allograft Vasculopathy. *J Heart Lung Transplant* 2009.
123. E Shao, M Kawano, N Moradzadeh, A Ankrom, K Kiyosaki, J Patel, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. Right Ventricular Dysfunction Immediately Post Transplant - A Marker for Poor Outcome? *J Heart Lung Transplant* 2009.
124. J Patel, E Shao, J Patel, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. Pre-Transplant FEV1/FVC but not FEV1 alone by Pulmonary Function Testing Predicts Poor Outcome After Heart Transplantation: The Bane of COPD. *J Heart Lung Transplant* 2009.
125. J Patel, B Kubak, M Kawano, A Ankrom, M Yajnik, K Kiyosaki, M Kittleson, **J Moriguchi**, A Ardehali, J Kobashigawa. The Efficacy of Shorter Duration CMV Prophylaxis After Heart Transplantation. *J Heart Lung Transplant* 2009.
126. K Kiyosaki, J Kobashigawa, J Patel, J Patel, A Ankrom, M Kittleson, M Kawano, **J Moriguchi**, E Shao, A Ardehali. The Benefit of Immune Monitoring (Cylex): A Review of 864 Immune Monitoring Assays in Heart Transplantation. *J Heart Lung Transplant* 2009.
127. K Lo, K Kiyosaki, J Kobashigawa, M Kawano, A Ankrom, M Kittleson, E Shao, **J Moriguchi**, J Patel, A Ardehali. Low Peak Oxygen Consumption by Cardiopulmonary Stress Testing After Heart Transplantation Predicts Poor Outcome. *J Heart Lung Transplant* 2009.
128. B Kim, K Kiyosaki, E Shao, J Patel, M Kittleson, M Kawano, A Ankrom, **J Moriguchi**, A Ardehali, J Kobashigawa. Early Permanent Pacemaker After Heart Transplantation is a Surrogate Marker for Poor Outcome: Possible Immune Mechanisms. *J Heart Lung Transplant* 2009.

129. J Patel, K Kiyosaki, B Kubak, M Kawano, A Ankrom, M Kittleson, E Shao, **J Moriguchi**, A Ardehali, J Kobashigawa. Surreptitious Aspergillus Colonization is Not Associated with Poor Outcome While on Suppressive Azole Therapy. *J Heart Lung Transplant* 2009.
130. E Moreno, A Velleca, M Kawano, K Kiyosaki, S Wong, A Ankrom, J Patel, M Kittleson, L Ventura, **J Moriguchi**, A Ardehali, J Kobashigawa. Does High Risk Status Identified by Pre-Transplant Social Worker and Psychiatric Evaluation Predict Outcome After Heart Transplant? *J Heart Lung Transplant* 2009
131. Patel J, Kittleson M, Reed E, Aguas G, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, **Moriguchi J**, Ardehali A, Kobashigawa J. The Importance of Anti-HLA DQ Antibodies as a Risk Factor for the Development of Transplant Coronary Artery Disease (TCAD) After Heart Transplantation. *J Heart Lung Transplant*. 2010; 29(2): S73-S74
132. Kittleson M, Patel J, Reed E, Gjertson D, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, **Moriguchi J**, Ardehali A, Kobashigawa J. Accommodation after Heart Transplantation: Does it Exist? *J Heart Lung Transplant*. 2010; 29(2): S63
133. . Lai C, Patel J, Fishbein M, Kittleson M, Share M, Davis S, Kawano M, **Moriguchi J**, Ardehali A, Kobashigawa J. C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome. *J Heart Lung Transplant*. 2010; 29(2): S38.
134. Moreno E, Velleca A, Burch C, Patel J, Kittleson M, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome? *J Heart Lung Transplant*. 2010; (29)2: S60.
135. Kittleson M, Patel J, **Moriguchi J**, Kawano M, Patel K, Davis S, Hage A, Hamilton M, Ardehali A, Kobashigawa J. Heart Transplant Rejection with Cardiogenic Shock Supported with Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience. *J Heart Lung Transplant*. 2010; 29(2): S91.
136. Velleca A, Burch C, Montgomery S, Lockhart D, Patel J, Kittleson M, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. The Threat of Medication Miscommunication in Non-English-Speaking Heart Transplant Recipients. *J Heart Lung Transplant*. 2010; 29(2): S125.
137. Kawano M, Kittleson M, Fishbein M, Patel J, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Review of 12,703 Endomyocardial Biopsies: The Truth of Quilty Lesions in the Cyclosporine and Tacrolimus Era. *J Heart Lung Transplant*. 2010; 29(2): S73.
138. Kawano M, Patel J, Kittleson M, Reed E, Gjertson D, Cecka M, Velleca A, Stimpson E, Burch C, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. The Incidence and Outcome of Sensitization in Patients Awaiting Re-do Heart Transplantation. *J Heart Lung Transplant*. 2010; 29(2): S123-S124.
139. Patel J, Kittleson M, Reed E, Zhang Q, Rajalingam R, Velleca A, Stimpson E, Burch C, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does it Make Sense to Desensitize? *J Heart Lung Transplant*. 2010; 29(2): S103-S104.
140. Kittleson M, Patel J, Azarbal B, **Moriguchi J**, Kawano M, Davis S, Hage A, Ardehali A, Kobashigawa J. First Angioplasty Does Not Appear to Alter Outcome in Heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease. *J Heart Lung Transplant*. 2010; 29(2): S124.

141. Patel J, Kittleson M, Zhang Q, Reed E, Kawano M, Davis S, Cecka M, Burch C, Velleca A, Stimpson E, **Moriguchi J**, Ardehali A, Kobashigawa J. Are Circulating Antibodies Necessary To Make A Diagnosis Of Antibody-Mediated Rejection? *J Heart Lung Transplant*. 2010; 29(2): S54.
142. Kittleson M, Patel J, Reed E, Zhang Q, Cecka M, Stimpson E, Velleca A, Burch C, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Does MFI Quantitation Of Circulating Antibodies Correlate With Positive Cytotoxicity? *J Heart Lung Transplant*. 2010; 29(2): S152.
143. Kittleson M, Patel J, **Moriguchi J**, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. The Adverse Effects of Sirolimus in Heart Transplant Patients: Is it Worth it? *J Heart Lung Transplant*. 2010; 29(2): S22.
144. Patel J, Kittleson M, Share M, Kawano M, Davis S, Fishbein M, Lai C, **Moriguchi J**, Ardehali A, Kobashigawa J. Persistent Pulmonary Hypertension In Heart Transplant Patients: Is This A Recipe For Long-Term Failure? *J Heart Lung Transplant*. 2010; 29(2): S92.
145. Patel J, Kittleson M, Kubak B, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Asymptomatic Positive CMV Serology is Associated with Increased Risk for the Development of Transplant Coronary Artery Disease (TCAD): Who Needs Symptoms? *J Heart Lung Transplant*. 2010; 29(2): S124.
146. Patel J, Kittleson M, Kubak B, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Development Of Cytomegalovirus (CMV) Infection During Ongoing Valganciclovir Therapy. *J Heart Lung Transplant*. 2010; (29)2: S66-S67.
147. Shemin R, Patel J, Ardehali A, Kittleson M, Kawano M, Davis S, **Moriguchi J**, Kobashigawa J. Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes. *J Heart Lung Transplant*. 2010; 29(2): S102.
148. Montgomery S, Kawano M, Lockhart D, Velleca A, Burch C, Patel J, Davis S, Kittleson M, **Moriguchi J**, Ardehali A, Kobashigawa J. Does Race Mismatch Have An Impact On Outcome After Heart Transplantation? *J Heart Lung Transplant*. 2010; 29(2): S124-S125.
149. Patel J, Kittleson M, Azarbal B, Hage A, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Does A Normal Angiogram Further From Heart Transplantation Confer Less Chance To Develop CAV? Should We Still Do Annual Angiograms Late After Transplantation? *J Heart Lung Transplant*. 2010; 29(2): S53.
150. Burch C, Amegatcher A, Patel J, Kittleson M, Kawano M, Davis S, Goldstein Z, **Moriguchi J**, Ardehali A, Kobashigawa J. Transition Of Pediatric Heart Transplant Patients To The Adult Heart Transplant Program: Are They Doomed To Be Rejected? *J Heart Lung Transplant*. 2010; 29(2): S33.
151. Kittleson M, **Moriguchi J**, Kwon M, Reed E, Davis S, Kawano M, Burch C, Velleca A, Stimpson E, Patel J, Ardehali A, Kobashigawa J. Highly Sensitized Patients on VAD Support awaiting Heart Transplant on a Ventricular Assist Device (VAD) Appear to have a Less Robust Immune Response Compared to Non-VAD Patients. *J Heart Lung Transplant*. 2010; 29(2): S120.
152. Lockhart D, Doering L, Burch C, Montgomery S, Velleca A, Patel J, Kittleson M, Davis S, Kawano M, Goldstein Z, Moradzadeh A, **Moriguchi J**, Ardehali A, Kobashigawa J. Are Recipients From Heart

Donors Listed as Homeless at Increased Risk for Poor Outcome After Heart Transplantation? *J Heart Lung Transplant*. 2010; 29(2): S39.

153. Kwon M, **Moriguchi J**, Kittleson M, Patel J, Kawano M, Davis S, Reed E, Burch C, Velleca A, Stimpson E, Ardehali A, Kobashigawa J. Lack of Sensitization In Patients Awaiting Heart Transplantation On Heartmate II Axial Flow Assist Devices. *J Heart Lung Transplant*. 2010; 29(2): S183.
154. Davis S, Patel J, Kittleson M, Kawano M, **Moriguchi J**, Hamilton M, Ardehali A, Kobashigawa J. Potential Immunomodulatory Effects of Granulocyte Colony Stimulating Factor (GCSF) in Heart Transplant Patients. *Am J Transplant*. 2010;10(S4):407.
155. Kawano M, Patel J, Kittleson M, Hamilton M, Hage A, Moradzadeh A, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. The Effects of Donor Height in Heart Transplant Patients on Triple Drug Immunosuppression. *Am J Transplant*. 2010;10(S4):310.
156. Kittleson M, Patel J, **Moriguchi J**, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. Splenectomy Prior to Heart Transplantation Does Not Affect Risk for Rejection and/or Infection after Heart Transplantation in Patients on Triple Drug Immunosuppression. *Am J Transplant*. 2010;10(S4):407.
157. Kittleson M, Patel J, Kawano M, Davis S, Share M, **Moriguchi J**, Hamilton M, Ardehali A, Kobashigawa J. Safety and Efficacy of Sildenafil in the 1<sup>st</sup> Year after Heart Transplantation for Pulmonary Hypertension. *Am J Transplant*. 2010;10(S4):307.
158. Azarbal B, Patel J, Kittleson M, Davis S, Kawano M, Moradzadeh A, Goldstein Z, **Moriguchi J**, Ardehali A, Kobashigawa J. Treadmill Nuclear Stress Testing Appears Effective to Detect Coronary Ischemia in Heart Transplant Patients with Established Transplant Coronary Artery Disease. *Am J Transplant*. 2010;10(S4):309.
159. Patel J, Kittleson M, Davis S, Kawano M, **Moriguchi J**, Ardehali A, Kobashigawa J. 10-Year Follow-up of Hepatitis C Donor Hearts in Triple-Drug Immunosuppression: The Final Nail in the Coffin. *Am J Transplant*. 2010;10(S4):120.
160. Patel J, Kittleson M, Kawano M, Davis S, **Moriguchi J**, Ardehali A, Kobashigawa J. Are Quilty B Lesions in Heart Transplant Biopsies in Patients on Tacrolimus Immunosuppression Harbingers of Rejection? A Review of 3651 Endomyocardial Biopsies. *Am J Transplant*. 2010;10(S4):404.
161. Kittleson M, Kawano M, Goldstein Z, Rafiei M, Azarbal B, **Moriguchi J**, Hage A, Reinsmoen N, Reed E, Luthringer D, Esmailian F, Kobashigawa J. Does the Detection of Circulating Donor-Specific Antibody Impact Pathology Diagnosed Antibody-Mediated Rejection after Heart Transplant? *J Heart Lung Transplant*. 2011; 30(4, Supplement): S17. \
162. Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, **Moriguchi J**, Reinsmoen N, Reed E, Hage A, Trento A, Kobashigawa J. Pre-Transplant Strength of Circulating Antibody as Expressed in the Calculated Panel Reactive Antibody Score Predicts Antibody-Mediated Rejection after Heart Transplant. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S175.
163. Patel J, **Moriguchi J**, Stimpson E, Reinsmoen N, Reed E, Kawano M, Goldstein Z, Rafiei M, Hamilton M, Schwarz E, Kobashigawa J. Success of Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies in a Large Cohort of Sensitized Heart Transplant Candidates. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S175.

164. Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, **Moriguchi J**, Czer L, Esmailian F, Kobashigawa J. Challenging the ISHLT Guideline Regarding Switch from Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S182.
165. **Moriguchi J**, Patel J, Kittleson M, Rafiei M, Stern L, Czer L, Trento A, Kobashigawa J. Older Patients with Hemodynamic Compromise Rejection: What Happened to Immunosenescence? *J Heart and Lung Transplant*. 2012; 31(4): S233.
166. **Moriguchi J**, Patel J, Kittleson M, Rafiei M, Stern L, Chai W, Chang D, Trento A, Czer L, Kobashigawa J. Risk for Deep Vein Thrombosis and Pulmonary Embolism after Heart Transplantation: Characterization of an Old Problem. *J Heart and Lung Transplant*. 2012; 31(4): S235.
167. Kansara P, Kransdorf E, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Czer L, Trento A, Kass R, Esmailian F, Kobashigawa J, **Moriguchi J**. Improved Outcomes in “Crash and Burn” Patients through BiVAD Support. *J Heart and Lung Transplant*. 2012; 31(4): S267-S268.
168. **Moriguchi J**, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Chang D, Czer L, Trento A, Esmailian F, Kobashigawa J. Are Sensitized VAD Patients Similar to Sensitized non-VAD Patients in Terms of Outcome? *Am J Transplant*. 2012; 12 (Suppl 3): 120-121.
169. Kansara P, Czer L, Patel J, Kittleson M, Mirocha J, **Moriguchi J**, Chang D, De Robertis M, Trento A, Kass R, and Kobashigawa J. Prior Cardiac Surgery is a Predictor of Mortality in the First-Year in Heart Transplant Recipients. *Am J Transplant*. 2012; 12 (Suppl 3): 476.
170. Kansara P, Czer L, Patel J, Mirocha J, Kittleson M, De Robertis M, **Moriguchi J**, Chang D, Ramzy D, Kass R, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in Heart Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing Database. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196
171. Tadwalkar R, Kittleson M, Patel J, **Moriguchi J**, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. Establishing a PRA Threshold to Treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 163
172. Patel J, Kittleson M, Rafiei M, Osborne A, Aaronson A, Chang D, Azarbal B, Czer L, **Moriguchi J**, Kobashigawa J. Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S50
173. Kobashigawa J, Tadwalkar R, Kittleson M, Patel J, **Moriguchi J**, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N. Establishing a PRA Threshold to treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Heart and Lung Transplant*. 2013; 32(4): S53
174. Morlend R, Kittleson M, Patel J, Rafiei M, Osborne A, Hage A, Chang D, Czer L, **Moriguchi J**, Trento A, Kobashigawa J. Complications on the Heart Transplant Waiting List is Common: Reducing Wait List Time for Sensitized Patients May Avoid Complications. *J Heart and Lung Transplant*. 2013; 32(4): S208
175. Kittleson M, Patel J, Rafiei M, Osborne A, Shiozaki R, Chang D, **Moriguchi J**, Czer L, Kobashigawa J. Failed Prednisone Taper Off after heart transplant: Is there a price to be paid? *J Heart and Lung Transplant*. 2013; 32(4): S200

176. Piponnier L, Kittleson M, Patel J, Rafiei M, Osborne A, Dhiantravan V, Chang D, Czer L, Hage A, Hamilton M, **Moriguchi J**, Kobashigawa J. Mycophenolate not Azathioprine is Associated with Increased Risk for Skin Cancer after Heart Transplant. *J Heart and Lung Transplant*. 2013; 32(4): S199
177. ISHLT mini-oral presentation: San Diego, CA 2014 “ECMO as a Bridge to decision in INTERMACS 1 Profile patients”
178. World Transplant Congress 2014 SF, CA “Heart Transplant vs DT LVAD in Elderly, Are They Comparable?”
179. Gurudevan S, Arabia F, Esmailian, Ramzy D, Czer L, Kobashigawa J, **Moriguchi J**. The Total Artificial Heart: An Effective Bridge to Transplantation in Patients with Advanced Heart Failure. *J Am Coll Cardiol*. 2014; 63 (12\_S)
180. **Moriguchi J**, Arabia F, Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Chang DH, Czer L, Hage A, Ramzy D, Kobashigawa J. Does VAD Placement Reduce Weight in Obese Severe Heart Failure Patients? *J Heart Lung Transplant*. 2014; 33(4): S209
181. **Moriguchi J**, Arabia F, Jocson R, Patel J, Kittleson M, Liou F, Yu Z, Ernst W, Hamilton M, Chang DH, Czer L, Kobashigawa J. Extracorporeal membrane Oxygenation as a Bridge to Decision for INTERMACS 1 Patients. *J Heart Lung Transplant*. 2014; 33(4): S250-251
182. Kobashigawa J, **Moriguchi J**, Reinsmoen N, Kittleson M, Yu Z, Liou F, Ngan A, Runyan M, Henry H, Chang DH, Czer L, Arabia F. Sensitized VADs vs. Sensitized Non-VADs: Is There an Immunological Difference? *J Heart Lung Transplant*. 2014; 33(4): S305
183. Balasubramanya S, Arabia F, Trento A, Ramzy D, Chang DH, Kittleson M, Czer L, **Moriguchi J**, Kobashigawa J. Extracorporeal Membrane Oxygenation as a Bridge to Recovery, Bridge to Ventricular Assist Device and Bridge to Heart Transplantation: A Retrospective Review of Data from a Single Tertiary Care Institution. *J Heart Lung Transplant*. 2014; 33(4): S78
184. **Moriguchi J**, Arabia F, Kittleson M, Patel J, Yu Z, Liou F, Ernst W, Huie N, Hage A, Chang D, Czer L, Kobashigawa J. Heart Transplantation vs. Ventricular Assist Device as Destination Therapy in Older Patients: Are They Comparable? *Am J Transplant*. 2014; 14(S3): 52
185. Arabia F, Moriguchi, Jocson R, Kittleson M, Patel J, Yu Z, Liou F, Chang D, Czer L, Ramzy D, Esmailian F, Kobashigawa J. Single Center Experience of Total Artificial Heart as a Bridge to Heart Transplantation. *Am J Transplant*. 2014; 14(S3): 52
186. Patel J, Kittleson M, Ramzy D, Yu Z, Liou F, Yabuno J, Arabia F, **Moriguchi J**, Czer L, Kobashigawa J. Perioperative Bleeding Risk of Anti-Platelet Therapy Prior to Heart Transplant. *Am J Transplant*. 2014; 14(S3): 59
187. Azarbal B, Chang D, Esmailian F, Arabia F, **Moriguchi J**, Kobashigawa J, Makkar R. No Survival Benefit with Use of Intra-Aortic Balloon Pump in Extracorporeal Membrane Oxygenation: A Pooled Experience of 1,517 Patients. *J Am Coll Cardiol*. 2014;64(11\_S)
188. Kobashigawa J, Kittleson M, **Moriguchi J**, Yu Z, Liou F, Luu M, Hamilton M, Chang M, Geft D, Esmailian F. How Old Is Too Old for Simultaneous Heart Kidney Donation? *Am J Transplant*. 2014; 14(S3): 425



189. Patel J, Kittleson M, **Moriguchi J**, Liou F, Yu Z, Yabuno J, Azarbal B, Chang D, Czer L, Kobashigawa J. Cyclosporine vs. Tacrolimus: Which Is a Better Match With Everolimus? *Am J Transplant*. 2014; 14(S3): 430
190. Cheng R, Azarbal B, Herr J, Ramzy D, Kobashigawa J, Arabia F, Moriguchi F. Early Crossover from Extracorporeal Membrane Oxygenation to More Durable Mechanical Circulatory Support Increases Survival to Transplant or Recovery. *J Heart Lung Transplant*. 2015; 34(4): S1-S368
191. Arabia F, Kittleson M, Czer L, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J, **Moriguchi J**. The Risk of Hospital Readmissions Following Mechanical Circulatory Support Placement. *J Heart Lung Transplant*. 2015; 34(4): S126
192. Runyan C, Arabia F, Czer L, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH, Kobashigawa J, **Moriguchi J**. Left Ventricular Assist Devices vs. Total Artificial Hearts: Which Causes More Cerebrovascular Accidents. *J Heart Lung Transplant*. 2015; 34(4): S213
193. Ghafourian K, **Moriguchi J**, Kittleson, Czer L, Passano E, Liou F, Huie N, Chang DH, Trento A, Arabia F, Kobashigawa J. Drop in Estimated Glomerular Filtration Rate at 1 Year after Heart Transplantation – Concern for Poor Outcome. *J Heart Lung Transplant*. 2015; 34(4): S92
194. Runyan C, **Moriguchi J**, Kittleson M, Czer L, Passano E, Liou F, Chang DH, Ramzy, Esmailian F, Kobashigawa J, Arabia F. Reliability of the Freedom Driver after Total Artificial Heart Implantation. *J Heart Lung Transplant*. 2015; 34(4): S276–S277
195. Henry H, Arabia F, Kittleson M, Czer L, Passano E, Yabuno J, Siddiqui S, Antifantis E, Chang DH, Kobashigawa J, **Moriguchi J**. Does the Specific Type of Caregiver Impact Readmission after Mechanical Circulatory Support Device Placement? *J Heart Lung Transplant*. 2015; 34(4): S230
196. McMenamy M, Arabia F, Czer L, Kittleson M, Passano E, Liou F, Yabuno J, Chang DH, Esmailian F, Kobashigawa J, **Moriguchi J**. Breaking the Myth of Obesity as a Contraindication to Continuous Flow Left Ventricular Assist Devices. *J Heart Lung Transplant*. 2015; 34(4): S193
197. Arabia F, Czer L, Kittleson M, Passano E, Yabuno J, Liou F, Siddiqui S, Chang DH, Ramzy D, Kobashigawa J, **Moriguchi J**. Does Gender Make a Difference after Total Artificial Heart Implantation? *J Heart Lung Transplant*. 2015; 34(4): S219-S220
198. Cheng R, Azarbal B, Esmailian F, Trento A, Kobashigawa J, Arabia F, **Moriguchi J**. Initial Implant of Ventricular Assist Devices in INTERMACS Profiles 1 and 2 Patients in Refractory Cardiogenic Shock Improves Survival to Transplant Recovery. *J Heart Lung Transplant*. 2015; 34(4)
199. Koomalsingh K, Kiankhooy A, Ramzy D, Esmailian F, Trento A, **Moriguchi J**, Kobashigawa J, Arabia F. The Total Artificial Heart (TAH) Experience at Cedars Sinai Medical Center. *J Heart Lung Transplant*. 2015; 34(4); S219
200. Arabia F, L Czer, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH, Esmailian, Kobashigawa J, **Moriguchi J**. The Selection Process for the Total Artificial Heart. *Am J Transplant*. 2015; 15(3)70
201. Jamero G, **Moriguchi J**, Czer L, Kittleson M, Siddiqui S, Liou F, Arman D, Lam L, Chang DH, Zakowski P, Kobashigawa J, Arabia F. Anti-Thymocyte Globulin Induction in Infected Mechanical Circulatory Support Patients: Is it Safe? *Am J Transplant*. 2015; 15(3)

202. Arabia F, Kittleson M, Czer L, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J, **Moriguchi J**. Assessment of Hospital Readmissions after Mechanical Circulatory Support. *Am J Transplant*. 2015; 15(3)
203. Neyer J, Kittleson M, Patel J, Czer L, Aintablian T, Rodriguez G, Jocson R, Runyan C, Chang D, **Moriguchi J**, Trento A, Kobashigawa J. Desensitization in Total Artificial Heart Patients. *J Heart Lung Transplant*. 2016; 35(4): S287.
204. Runyan C, Henry H, Huie N, **Moriguchi J**, Kittleson M, Czer L, Chang D, Passano E, Aintablian T, Kobashigawa J, Esmailian F, Arabia F. Can Patients with Restrictive Physiology Be Successfully Bridged to Transplant with left Ventricular Support Alone Versus Biventricular Support? *J Heart Lung Transplant*. 2016; 35(4): S283-384.
205. Kittleson M, Patel J, Czer L, Passano E, Aintablian T, Runyan C, Henry H, Chang D, Esmailian F, **Moriguchi J**, Kobashigawa J. Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients. *J Heart Lung Transplant*. 2016; 35(4): S262.
206. **Moriguchi J**, Kittleson M, Patel J, Czer L, Aintablian T, Jocson R, Runyan C, Chang D, Azarbal B, Arabia F, Kobashigawa J. Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production. *J Heart Lung Transplant*. 2016; 35(4): S295.
207. **J. Moriguchi**, L. Czer, H. Henry, R. Jocson, C. Runyan, T. Aintablian, E. Passano, D. Chang, D. Geft, F. Arabia. MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome? *J Heart Lung Transplant*. 2016; 35(4): S257-S258.
208. F. Arabia, I. Gregoric, V. Kasirajan, J. D. Moriguchi, D. C. Naftel, S. L. Myers, J. K. Kirklin. Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events in Intermacs *J Heart Lung Transplant*. 2016; 35(4): S95
209. L. D. Lam<sup>1</sup>, U. Duong<sup>2</sup>, L. Luu<sup>2</sup>, K. Del Rosario<sup>2</sup>, M. Fan<sup>2</sup>, P. Ambrose<sup>2</sup>, **J. Moriguchi**<sup>1</sup>, A. Francisco<sup>1</sup> Evaluating the Safety and Efficacy of Enoxaparin in Bridging Mechanical Circulatory Support (MCS) Patients from Subtherapeutic to Therapeutic INR in an Outpatient Setting *J Heart Lung Transplant*. 2016; 35(4) S396.
210. Arabia F, Kittleson M, Czer L, Chang D, Aintablian T, Passano E, Rodriguez G, Runyan C, Kobashigawa J, **Moriguchi J**. The Largest Single Center Experience with Total Artificial Heart Implantation: Characterization of Outcome. *Am J Transplant*. 2016;16; 16(3).
211. Carmelita Runyan, RN-BC, MSN, Heather Barone, RN, BSN, CCRN, Newman Huie, BSN, Jennifer Hajj, RN, BSN, Rhodora Jocson, RN-BC, MSN, PNP, CNS, Lee Lam, PharmD, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, MD, Jaime Moriguchi, MD, Francisco Arabia, MD, MBA. A Comparison of Driveline Infections: Left Ventricular Assist Device Vs. Total Artificial Heart. Cedars-Sinai, Los Angeles. Abstract #2701692
212. Heather Barone, Jennifer Hajj, Carmelita Runyan, Newman Huie, Rhodora Jocson, Dael Geft, Elizabeth Passano, Lawrence Czer, Jaime Moriguchi, Jon Kobashigawa, and Francisco Arabia. Managing Driveline Repairs in Total Artificial Heart Patients: A Single Center Experience. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S419.

213. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Michele Hamilton, Dael Geft, Evan Kransdorf, Lawrence Czer, Jon Kobashigawa, Francisco Arabia, and Jaime Moriguchi. Does Socioeconomic Status Impact Outcome following Mechanical Circulatory Support Device Implantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S435–S436.
214. Richard Cheng, Danny Ramzy, Babak Azarbal, Fardad Esmailian, Dael Geft, David Chang, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. Clinical Outcomes of Impella Microaxillary Pumps When Used in Patients with Cardiogenic Shock Bridged Successfully to Durable Mechanical Circulatory Support and Cardiac Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S139.
215. Jon Kobashigawa, Tamar Aintablian, Danny Ramzy, Alfredo Trent, Joshua Chung, Jaime Moriguchi, Lawrence Czer, David Chang, Michele Hamilton, Michelle Kittleson, and Fardad Esmailian. Immediate ECMO Support after Heart Transplantation: Does it Portend Reasonable Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4): S429-S430.
216. Rajeev Mohan, Jonathan Neyer, Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Ryan Levine, David Chang, Lawrence Czer, Jaime Moriguchi, Jon Kobashigawa, and Francisco Arabia. Pre-Implant Moderate-Severe Fibrosis on Liver Biopsy Predicts Adverse Outcomes After Mechanical Circulatory Support. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S124–S125.
217. Jaime Moriguchi, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, James Kwan, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, Jon Kobashigawa, and Francisco Arabia. Combined Heart-Kidney Transplant vs Heart Alone Transplant in Patients with Total Artificial Heart: Are they Viable? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S329.
218. Heather Barone, Bernice Coleman, Harriet Aronow, Carmelita Runyan, Jennifer Hajj, Newman Huie, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. Implementing Practices to Improve Self-Care Among Caregivers of Patients with Mechanical Circulatory Support. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S359–S360.
219. Bernice Coleman, Heather Barone, Harriet Aronow, Carmelita Runyan, Jennifer Hajj, Newman Huie, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. Mechanical Circulatory Support Caregiver Gender Burden and Benefit: Is There a Difference? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S358–S359.
220. Antonio Conte, Jennifer Hajj, Stephen Yang, Elizabeth Passano, Heather Barone, David Chang, Fardad Esmailian, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. Utilization of Transverse Abdominis Plexus Block for Treatment of Left Ventricular Assist Device Associated Driveline Pain / Abdominal Pain Refractory to Conventional Multi-Modal Therapy: A Case Series? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S358.
221. Andriana Nikolova, Dael Geft, David Chang, Joshua Chung, Rhodora Jocson, Tamar Aintablian, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. What Factors Influence Right Ventricular Function Improvement in the Setting of Pulmonary Arterial Pressure Normalization After Left Ventricular Assist Device Placement? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S351–S352.
222. Heidi Reich, Danny Ramzy, James Mirocha, Mick De Robertis, Joshua Chung, Fardad Esmailian, David Chang, Jaime Moriguchi, Lawrence Czer, Alfredo Trento, and Francisco Arabia, 2017. Not all

INTERMACS Level 1's are the Same: Survival After Total Artificial Heart Implantation with or without Temporary Circulatory Support. *The Journal of Heart and Lung Transplantation*, 36(4), S348-S349.

223. Oksana Volod, Lee Lam, Mark Barglowski, James Mirocha, Carmelita Runyan, Jaime Moriguchi, Lawrence Czer, and Francisco Arabia, 2017. Comparison of Activated Partial Thromboplastin Time (aPTT) and Anti-Factor Xa for Low Intensity Unfractionated Heparin Monitoring in Patients with Mechanical Circulatory Support Devices (MCS). *The Journal of Heart and Lung Transplantation*, 36(4), S443.
224. Rafiei, Matthew MS, Moriguchi, Jaime MD, Kittleson, Michelle MD, PhD, Patel, Jignesh MD, PhD, Aintablian, Tamar BS, Passano, Elizabeth MS, Sharoff, Rayshma BS, Kwan, James BS, Kransdorf, Evan MD, PhD, Chang, David MD, Czer, Lawrence MD, Kobashigawa, Jon MD and Francisco Arabia, MD, MBA. Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients? Cedars Sinai Heart Institute, Los Angeles, United States. American Transplant Congress; 2017; April 29th -May 3rd; Chicago. Abstract nr 250666.
225. David Chang, MD, Michelle Kittleson, MD, PhD, Jignesh Patel, MD, PhD, Tamar Aintablian, BS, Ryan Levine, BS, Newman Huie, BSN, Evan Kransdorf, MD, PhD, Dael Geft, MD, Lawrence Czer, MD, Jon Kobashigawa, MD, Francisco Arabia, MD, MBA, and Jaime Moriguchi, MD. Weight Loss in Patients with Left Ventricular Assist Device Positioned Above or Below the Diaphragm for Patients with Severe Heart-Failure: Does it Make a Difference? *ASAIO Journal* 2017. Cedars-Sinai, Los Angeles.
226. Carmelita Runyan, RN-BC, MSN, Newman Huie, BSN, Jennifer Hajj, RN, BSN, Lee Lam, PharmD, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, MS, Jaime Moriguchi, MD, and Francisco Arabia, MD, MBA. A Comparison of Driveline Infections: Left Ventricular Assist Device Vs Total Artificial Heart. *ASAIO Journal* 2017. Cedars-Sinai, Los Angeles.
227. Heather Barone, RN, BSN, CCRN, Harriet Aranow, PhD, Carmelita Runyan, RN-BC, Jennifer Hajj, RN, BSN, Newman Huie, BSN, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, MS, Jaime Moriguchi, MD, and Francisco Arabia, MD, MBA. Left Ventricular Assist Device Versus Total Artificial Heart: Do Patients Report the Same Energy Level? *ASAIO Journal* 2017. Cedars-Sinai, Los Angeles.
228. Newman Huie, BSN, Carmelita Runyan, RN-BC, Jennifer Hajj, RN, BSN, Rhodora Jocson, RN-BC, MSN, PNP, CNS, Tamar Aintablian, BS, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, Jaime Moriguchi, MD, and Francisco Arabia, MD, MBA. Unplanned Readmissions 6 Months Post-Discharge: Left Ventricular Assist Device Versus Total Artificial Heart. *ASAIO Journal* 2017. Cedars-Sinai, Los Angeles.
229. Fardad Esmailian, MD, Dominick Megna, MD, Sadia Dimbil, BS, Ryan Levine, BS, Jaime Moriguchi, MD, Lawrence Czer, MD, Francisco Arabia, MD, MBA, and Jon Kobashigawa, MD. Does Durable Mechanical Circulatory Support have an Impact on Outcome of Heart-Kidney Transplantation? *European Journal of Cardiothoracic Surgery*. Cedars-Sinai, Los Angeles. Abstract #000407
230. X. Zhang, J. Mirocha, T. Aintablian, **J. Moriguchi**, F. Arabia, J.A. Kobashigawa, N.L. Reinsmoen. Revealing a New Mode of Sensitization Induced by Mechanical Circulatory Support Devices (MCS): Impact of Anti-AT1R Antibodies. *The Journal of Heart and Lung Transplantation*, 2017, 36(4); S32-33.
231. F. Esmailian, F. Arabia, L. Czer, M. Kittleson, D. Geft, R. Cole, G. Esmailian, M. Rafiei, E. Passano, H. Barone, **J. Moriguchi**. Does the Type of Mechanical Circulatory Support as a Bridge to Heart Transplant Affect Outcome after Transplant? *The Journal of Heart and Lung Transplantation*, 2018, 37(4); S289.

232. O. Volod, B. Coleman, L.D. Lam, M. Pollack, D. Collier, R. Lee, D. Mochizuki, L.S. Czer, **J. Moriguchi**, J.A. Kobashigawa, F.A. Arabia. Utility of Hypercoagulable Work-Up in Predicting Post-Operative Complications in Total Artificial Heart (TAH) Implant Patients. *The Journal of Heart and Lung Transportation*, 2018, 37(4); S371.
233. L.S. Czer, L. Lam, R. Hays, F. Baiesc, A. Kuo, S. Hariri, **J. Moriguchi**, F. Arabia, O. Volod. Correlation of High Molecular Weight Von Willebrand Factor Multimer loss and Rotational Speed During Short Term Mechanical Circulatory Support. *The Journal of Heart and Lung Transportation*, 2018, 37(4); S379-380.
234. Clinical Advancements in Cardiovascular Care, Pomona, CA “Mechanical Circulatory Support in Advanced Heart Failure and Cardiogenic Shock”, March 2019
235. F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, D. Geft, J. Chung, D. Ramzy, **J. Moriguchi**, J. Kobashigawa. Acceptable Post-Heart Transplant Outcomes Support Temporary MCS as Status 2 for the New UNOS Donor Heart Allocation Policy. *The Journal of Heart and Lung Transportation*, 2019, 38(4); S431.
236. F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, D. Geft, J. Chung, D. Ramzy, **J. Moriguchi**, J. Kobashigawa. Temporary MCS versus Durable MCS as a Bridge to Heart Transplantation. *The Journal of Heart and Lung Transportation*, 2019, 38(4); S344.
237. E. Kransdorf, J. Patel, M. Kittleson, D.H. Chang, R. Levine, S. Dimbil, A. Bitterman, A. Velleca, L. Czer, **J. Moriguchi**, F. Esmailian, J.A. Kobashigawa. Does Antibody-Mediated Rejection in the First-Month after Heart Transplant Lead to Poor Longer-Term Outcome? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S292.
238. J.S. Chung, D. Emerson, D. Ramzy, A. Akhmerov, R.M. Cole, D. Megna, F. Esmailian, **J. Moriguchi**, J.A. Kobashigawa, A. Trento. Temporary Mechanical Circulatory Support, a New Paradigm in Bridging Patients to Heart Transplantation: Comparing Outcomes versus Durable Left Ventricular Assist Devices. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S230-S231.
239. L.D. Lam, M. Payne-Cardona, M. Fang, R. Herra, E. Coria Mondragon, C. Runyan, **J. Moriguchi**, J.A. Kobashigawa, L.S. Czer, F. Arabia, R. Zabner. Comparing the Incidence of Surgical Site Infections (SSI) Using Narrow versus Broad-Spectrum Perioperative Antibiotic Prophylaxis in Mechanical Circulatory Support (MCS) Patients. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S102.
240. H. Barone, M. Olman, A. Fishman, L. Olanisa, C. Runyan, J. Hajj, N. Huie, M. Lindsay, E. Passano, J. Kobashigawa, **J. Moriguchi**, R. Cole, F. Esmailian, J. Chung, D. Ramzy. The Value of Licensed Clinical Social Worker Pre-Implant Assessment in Predicting Non-Compliance in Durable Mechanical Circulatory Support Deice Patients. *The Journal of Heart and Lung Transportation*, 2019, 38(4); S94.
241. A. Wolfson, M. Kittleson, J. Patel, E. Kransdorf, R. Cole, R. Levine, S. Dimbil, A. Lam, L. Czer, A. Hage, J. Chung, **J. Moriguchi**, J.A. Kobashigawa. Biopsy-Negative Rejection Late after Heart Transplantation: Impact on Long-Term Outcome. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S287-288.
242. D.H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, **J. Moriguchi**, D. Ramzy, J.A. Kobashigawa. Mechanical Circulatory Support Patients Awaiting Heart Transplant with

Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S210-S211.

243. Ramzy D, Cole R, Kittleson M, Levine R, Emerson D, Megna D, Esmailian F, **Moriguchi J**, Kobashigawa JA. A Retrospective Review of How the New UNOS Heart Transplant Donor Allocation Policy Affected Urgent Status Listing and Outcomes in Status 1, 2, and 3 Listing Compared to the Old Status 1A. *J Am Coll Cardiol*. 2020 Mar 24;75(11 S1):687.
244. Vaidya G, Cole R, Runyan C, Arabia FA, Megna D, Ramzy R, Emerson D, Esmailian F, Kobashigawa JA, **Moriguchi J**. Total Artificial Heart: Performance as a Bridge to Health and Survival. *J Am Coll Cardiol*. 2020 Mar 24;75(11 S1):757.
245. Nguyen VP, Cole R, **Moriguchi J**, Ramzy D, Kobashigawa JA. Donor Selection in Patients with Left Ventricular Assist Devices. *J Am Coll Cardiol*. 2020 Mar 24;75(11 S1):806.
246. L.D. Lam, L.S. Czer, N. Rafijah, K. Wong, F. Chen, D. Morovati, J. Shaffer, J. Hajj, N. Huie, M. Lindsay, M. Aguillon, E. Passano, C. Runyan, D. Ramzy, R. Cole, **J. Moriguchi**, and J. Kobashigawa. Mechanical Circulatory Support (MCS) Patients Bridged with Enoxaparin in the Outpatient Setting: Cedars-Sinai Medical Center Experience. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
247. C. Runyan, R. Zabner, D. Ramzy, F. Esmailian, D. Emerson, D. Megna, E. Passano, J. Hajj, N. Huie, M. Lindsay, M. Aguillon, L. Lam, D.H. Chang, J. Kobashigawa, **J. Moriguchi** and R. Cole. Increased Incidence of Cholecystitis with Total Artificial Heart versus Left Ventricular Assist Device. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
248. M. Kittleson, J. Patel, E. Kransdorf, A. Shen, K. Nishihara, S. Rajkumar, A. Velleca, D. Geft, L. Czer, **J. Moriguchi** and J. Kobashigawa. Desensitization Therapy for Mechanical Circulatory Support Patients with Existing Driveline Infection: Is It Safe with Current Desensitization Therapies? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
249. O. Seguchi, J. Youn, D. Geft, R. Cole, A. Shen, K. Nishihara, S. Mersola, C. Runyan, J. Hajj, D. Ramzy, J.A. Kobashigawa and **J. Moriguchi**. The Burden of Total Artificial Heart Patients and Complications after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
250. J. Youn, O. Seguchi, R. Cole, D. Geft, K. Nishihara, A. Shen, R. Sharoff, D. Ramzy, J. Kobashigawa and **J. Moriguchi**. Desensitization in Mechanical Circulatory Support Patients Awaiting Heart Transplantation: What is the Post-Transplant Outcome? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
251. A. Akhmerov, R.M. Cole, D. Megna, D. Emerson, L. Czer, F. Esmailian, J. Kobashigawa, D. Ramzy, J. Chikwe and **J. Moriguchi**. Impact of Bleeding Complications on Outcomes Following Total Artificial Heart Implantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
252. D. Ramzy, F. Esmailian, D. Emerson, D. Megna, R. Levine, R. Cole, E. Passano, C. Runyan, A. Velleca, J. Kobashigawa, and **J. Moriguchi**. The New UNOS Heart Allocation Changes Significantly Changed the Landscape of Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
253. D. Ramzy, F. Esmailian, D. Emerson, D. Megna, R. Levine, S. Mersola, R. Cole, E. Passano, C. Runyan, A. Velleca, J. Kobashigawa, and **J. Moriguchi**. Has the New Heart Transplant Donor Allocation Policy

Affected Immediate Post-Transplant Care and Outcomes? A Single Center Perspective. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.

254. Youn J, Cole R, Ramzy D, Kim E, Kobashigawa J, **Moriguchi J**. Three-Year Post-Transplant Outcome of Desensitized Mechanical Circulatory Support Patients Awaiting Heart Transplantation. *Am J Transplant*. 2020; 20 (suppl 3).